

25

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 July 2001 (05.07.2001)

PCT

(10) International Publication Number
WO 01/48183 A2

- (51) International Patent Classification⁷: **C12N 15/00**
- (21) International Application Number: **PCT/EP00/13149**
- (22) International Filing Date:
22 December 2000 (22.12.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
9930691.2 24 December 1999 (24.12.1999) GB
- (71) Applicant (for all designated States except US): **DEV-GEN NV** [BE/BE]; Technologiepark 9, B-9052 Zwijnaarde (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **PLAETINCK, Geert** [BE/BE]; Pontstraat 16, B-9820 Merelbeke (BE). **MORTIER, Katherine** [BE/BE]; Paddenhoek 20, B-9830 St.-Martens Latem (BE). **LISSENS, Ann** [BE/BE]; Tiensesteenweg 137, B-3010 Kessel-Lo (BE). **BOGAERT, Thierry** [BE/BE]; Wolvendreef 26g, B-8500 Kortrijk (BE).
- (74) Agent: **BAYLISS, Geoffrey, Cyril**; Boulton Wade Tennant, Verulam Gardens, 70 Gray's Inn Road, London WC1X 8BT (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— Without international search report and to be republished upon receipt of that report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/48183 A2

(54) Title: IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA INHIBITION

(57) Abstract: There are described ways of improving the efficiency of double stranded RNA inhibition as a method of inhibiting gene expression in nematode worms such as *C. elegans*. In particular, the invention relates to the finding that changes in the genetic background of *C. elegans* result in increased sensitivity to double-stranded RNA inhibition.

IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNAINHIBITION

5 The present invention is concerned with ways of
improving the efficiency of double stranded RNA
inhibition as a method of inhibiting gene expression
in nematode worms such as *C. elegans*. In particular,
the invention relates to the finding that the
susceptibility of nematode worms such as *C. elegans* to
10 double stranded RNA inhibition is affected by changes
in the genetic background of the worms.

It has recently been described in Nature Vol 391,
pp.806-811, February 98, that introducing double
stranded RNA into a cell results in potent and
15 specific interference with expression of endogenous
genes in the cell, which interference is substantially
more effective than providing either RNA strand
individually as proposed in antisense technology. This
specific reduction of the activity
20 of the gene was also found to occur in the nematode
worm *Caenorhabditis elegans* (*C. elegans*) when the RNA
was introduced into the genome or body cavity of the
worm.

The present inventors have utilized the double
25 stranded RNA inhibition technique and applied it
further to devise novel and inventive methods of (i)
assigning functions to genes or DNA fragments which
have been sequenced in various projects, such as, for
example, the human genome project and which have yet
30 to be accorded a particular function, and (ii)
identifying DNA responsible for conferring a
particular phenotype. Such methods are described in
the applicant's co-pending application number WO
00/01846. Processes for introducing RNA into a living
35 cell, either *in vivo* or *ex vivo*, in order to inhibit
expression of a target gene in that cell are

additionally described in WO 99/32619.

Several different experimental approaches can be used to introduce double-stranded RNA into nematode worms in order to achieve RNA interference *in vivo*.

5 One of the most straightforward approaches is simple injection of double-stranded RNA into a body cavity. A more elegant solution is to feed the nematodes on food organisms, generally bacteria, which express a double stranded RNA of the appropriate sequence,
10 corresponding to a region of the target gene.

The present inventors have now determined that the phenomenon of RNA interference in nematodes following ingestion of food organisms capable of expressing double-stranded RNA is dependent both on
15 the nature of the food organism and on the genetic background of the nematodes themselves. These findings may be exploited to provided improved methods of double-stranded RNA inhibition.

Therefore, according to a first aspect of the present invention there is provided a method of
20 inhibiting expression of a target gene in a nematode worm comprising feeding to said nematode worm a food organism which is capable of producing a double-stranded RNA structure having a nucleotide sequence
25 substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the nematode has a non wild-type genetic background selected to provide increased sensitivity to RNA interference as compared to wild
30 type.

Caenorhabditis elegans is the preferred nematode worm for use in the method of the invention although the method could be carried out with other nematodes and in particular with other microscopic nematodes,
35 preferably microscopic nematodes belonging to the genus *Caenorhabditis*. As used herein the term "microscopic" nematode encompasses nematodes of

approximately the same size as *C. elegans*, being of the order 1mm long in the adult stage. Microscopic nematodes of this approximate size can easily be grown in the wells of a multi-well plate of the type
5 generally used in the art to perform mid- to high-throughput screening.

It is an essential feature of this aspect of the invention that the nematode has a non wild-type genetic background which confers greater sensitivity
10 to RNA interference phenomena (abbreviated herein to RNAi) as compared to the equivalent wild type nematodes. As illustrated in the accompanying examples, introduction of double-stranded RNA (abbreviated herein to dsRNA) into a non wild-type
15 strain according to the invention results in greater inhibition of expression of the target gene. Depending on the nature of the target gene, this greater level of inhibition may be detectable at the phenotypic level as a more pronounced phenotype.

20 The nematode having non wild-type genetic background may, advantageously, be a mutant strain. Mutations which have the effect of increasing susceptibility of the nematode to RNAi may, for example, affect the stability of dsRNA or the kinetics
25 of dsRNA turnover within cells of the worm or the rate of uptake of dsRNA synthesised by a food organism. Suitable mutant strains include mutant strains exhibiting knock-out or loss-of-function mutations in one or more genes encoding proteins involved in RNA
30 synthesis, RNA degradation or the regulation of these processes.

In one preferred embodiment, the nematode is a mutant strain, more preferably a mutant *C. elegans*, which exhibits reduced activity of one or more
35 nucleases compared to wild-type. Suitable strains include mutant strains exhibiting knock-out or loss-of-function mutations in one or more genes encoding

nucleases, such as RNases. A particularly preferred example is the *nuc-1* strain. This mutant *C. elegans* strain is known per se in the art.

5 In a second preferred embodiment, the nematode is a mutant strain, more preferably a mutant *C. elegans*, which exhibits increased gut uptake compared to wild-type. Particularly preferred examples of such strains are the so-called *C. elegans* gun mutants described herein. In a still further embodiment, the nematode
10 may be a transgenic worm comprising one or more transgenes which increase gut uptake relative to wild-type.

The term "increased gut uptake" as used herein is taken to mean increased uptake of foreign particles
15 from the gut lumen and may encompass both increased gut permeability and increased gut molecular transport compared to wild-type *C. elegans*.

C. elegans feeds by taking in liquid containing its food (e.g. bacteria). It then spits out the
20 liquid, crushes the food particles and internalises them into the gut lumen. This process is performed by the muscles of the pharynx. The process of taking up liquid and subsequently spitting it out is called pharyngeal pumping. Once the food particles have been
25 internalised via pharyngeal pumping their contents must cross the gut itself in order to reach target sites in the worm. There are multiple factors which effect the uptake of compounds from the gut lumen to the surrounding tissues. These include the action of
30 multi-drug resistance proteins, multi-drug resistance related proteins and the P450 cytochromes as well as other enzymes and mechanisms available for transport of molecules through the gut wall.

C. elegans mutants which exhibit increased uptake
35 of foreign molecules through the gut may be obtained from the *C. elegans* mutant collection at the C.

C. elegans Genetic Center, University of Minnesota, St Paul, Minnesota, or may be generated by standard methods. Such methods are described by Anderson in Methods in Cell Biology, Vol 48, "C. elegans: Modern biological analysis of an organism" Pages 31 to 58. Several selection rounds of the PCR technique can be performed to select a mutant worm with a deletion in a desired gene. Alternatively, a population of worms could be subjected to random mutagenesis and worms exhibiting the desired characteristic of increased gut uptake selected using a phenotypic screen, such as the dye uptake method described herein.

As an alternative to mutation, transgenic worms may be generated with the appropriate characteristics. Methods of preparing transgenic worms are well known in the art and are particularly described by Craig Mello and Andrew Fire, Methods in Cell Biology, Vol 48, Ed. H.F. Epstein and D.C. Shakes, Academic Press, pages 452-480.

Worms exhibiting the desired characteristics of increased gut uptake can be identified using a test devised by the inventors based on uptake of a marker precursor molecule which is cleaved by the action of enzymes present in the gut lumen to generate a marker molecule which produces a detectable signal, such as fluorescence. A suitable marker precursor molecule is the fluorescent dye precursor BCECF-AM available from Molecular Probes (Europe BV), Netherlands. This dye only becomes fluorescent when cleaved by esterases and maintained at a pH above 6. The pH of the gut lumen is usually 5 or below. Thus, any BCECF-AM taken up through the pharynx into the gut lumen is not fluorescent until cleaved and the cleaved portion has entered the cells surrounding the lumen which are at a higher pH. Thus, this dye is able to quickly identify mutant or otherwise modified worms which have increased gut transport or permeability. There is a

gradual increase in fluorescence in the tissues surrounding the gut while the gut lumen remains dark. The fluorescence can be detected at an excitation wavelength of 485 nm and an emission wavelength of 530 nm.

Specific examples of gun mutant strains isolated using this procedure which may be used in the method of the invention are strains bg77, bg84, bg85 and bg86, although it is to be understood that the invention is in no way limited to the use of these specific strains. The *C. elegans* gun mutant strain bg85 was deposited on 23 December 1999 at the BCCM/LMG culture collection, Laboratorium Voor Microbiologie, Universiteit Gent, K. L. Ledeganckstraat 35, B-9000, Gent, Belgium under accession number LMBP 5334CB. The phrase "the bg85 mutation" as used herein refers to the specific mutation(s) present in the bg85 strain which is/are responsible for conferring the gun phenotype.

It is also within the scope of the invention to use a non wild-type nematode strain, preferable a *C. elegans* strain, having multiple mutations which affect sensitivity to RNAi. A preferred type of multiple mutant is one having at least one mutation which results in reduced nuclease activity compared to wild type and at least one mutation which results in increased gut uptake compared to wild type. An example of such a mutant is a *C. elegans* strain having the *nuc-1* mutation and at least one further gun mutation. As exemplified herein, double mutants having the *nuc-1* mutation and a gun mutation exhibit enhanced sensitivity to RNAi as compared to either *nuc-1* or gun single mutants.

For the avoidance of doubt, where particular characteristics or properties of nematode worms are described herein by relative terms such as "enhanced"

or "increased" or "decreased" this should be taken to mean enhanced, increased or decreased relative to wild-type nematodes. In the case of *C. elegans*, wild-type is defined as the N2 Bristol strain which is well known to workers in the *C. elegans* field and has been extremely well characterised (see Methods in Cell Biology, Volume 48, *Caenorhabditis elegans*: Modern biological analysis of an organism, ed. by Henry F. Epstein and Diane C. Shakes, 1995 Academic Press; The nematode *Caenorhabditis elegans*, ed. by William Wood and the community of *C. elegans* researchers., 1988, Cold Spring Harbor Laboratory Press; *C. elegans* II, ed. by Donald L. Riddle, Thomas Blumenthal, Barbara J. Meyer and James R. Priess, 1997, Cold Spring Harbor Laboratory Press). The N2 strain can be obtained from the *C. elegans* Genetic Center, University of Minnesota, St Paul, Minnesota, USA.

The food organism for use in the above aspect of the invention is preferably a bacterium such as, for example, a strain of *E.coli*. It will, however, be appreciated that any other type of food organism on which nematodes feed and which is capable of producing dsRNA could be used. The food organism may be genetically modified to express a double-stranded RNA of the appropriate sequence, as will be understood with reference to the examples included herein. One convenient way in which this may be achieved in a bacterial food organism is by transforming the bacterium with a vector comprising a promoter or promoters positioned to drive transcription of a DNA sequence to RNA capable of forming a double-stranded structure. Examples of such vectors will be further described below.

The actual step of feeding the food organism to the nematode may be carried out according to procedures known in the art, see WO 00/01846.

Typically the feeding of the food organisms to the nematodes is performed on standard agar plates commonly used for culturing *C. elegans* in the laboratory. However, the step of feeding the food
5 organism to the nematodes may also be carried out in liquid culture, for example in the wells of 96-well microtitre assay plates.

The inventors have further observed that variations in the food organism can result in enhanced
10 *in vivo* RNAi when the food organism is ingested by a nematode worm.

Accordingly, in a further aspect the invention provides a method of inhibiting expression of a target gene in a nematode worm comprising feeding to said
15 nematode worm a food organism capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the food organism carries a
20 modification selected to provide increased expression or persistence of the double-stranded RNA compared to a food organism which does not carry the modification.

The modification present in the food organism can be any modification which results in increased
25 expression of the dsRNA or in increased persistence of the dsRNA. Suitable modifications might include mutations within the bacterial chromosome which affect RNA stability and/or degradation or mutations which have a direct effect on the rate of transcription. In
30 a preferred embodiment, the food organism is an RNase III minus *E. coli* strain, or any other RNase negative strain.

According to a still further aspect of the invention there is provided a method of inhibiting
35 expression of a target gene in a nematode worm comprising introduction of a DNA capable of producing a double-stranded RNA structure having a nucleotide

sequence substantially identical to a portion of said target gene in said nematode, wherein the nematode is one which exhibits increased gut uptake compared to wild type.

5 In addition to exhibiting increased sensitivity to RNAi following feeding with food organisms capable of expressing a dsRNA, nematodes which exhibit increase gut uptake as described herein also show increased uptake of DNA molecules capable of producing
10 double-stranded RNA structures following ingestion into a nematode.

 In a preferred embodiment, the DNA is in the form of a vector comprising a promoter or promoters orientated to relative to a sequence of DNA such that
15 they are capable of driving transcription of the said DNA to make RNA capable of forming a double-stranded structure upon binding of an appropriate RNA polymerase to the promoter or promoters.

 Several different arrangements of promoters may
20 be used in such a vector. In a first arrangement a DNA fragment corresponding to a region of the target gene is flanked by two opposable polymerase-specific promoters which are preferably identical. Transcription from the opposable promoters produces
25 two complementary RNA strands which can anneal to form an RNA duplex. The plasmid pGN1 described herein is an example of a vector comprising two opposable T7 promoters flanking a multiple cloning site for insertion of a DNA fragment of the appropriate
30 sequence, corresponding to a region of a target gene. pGN8 is an example of a vector derived from pGN1 containing a fragment of the *C. elegans unc-22* gene. In an alternative arrangement, DNA fragments corresponding to a region of the target gene may be
35 placed both in the sense and the antisense orientation downstream of a single promoter. In this case, the sense/antisense fragments are co-transcribed to

generate a single RNA strand which is self-complementary and can therefore form an RNA duplex.

In both of the above arrangements, the polymerase-specific T3, T7 and SP6 promoters, all of which are well known in the art, are useful for driving transcription of the RNA. Expression from these promoters is dependent on expression of the cognate polymerase. Advantageously, the nematode itself may be adapted to express the appropriate polymerase. Expression of the polymerase may be general and constitutive, but could also be regulated under a tissue-specific promoter, an inducible promoter, a temporally regulated promoter or a promoter having a combination of such characteristics. Transgenic *C. elegans* strains harboring a transgene encoding the desired polymerase under the control of an appropriately-regulated promoter can be constructed according to methods known *per se* in the art and described, for example, by Craig Mello and Andrew Fire in *Methods in Cell Biology*, Vol 48, Ed. H. F. Epstein and D. C. Shakes, Academic Press, pp 452-480.

The advantage of adapting the nematode to express the required polymerase is that it is possible to control inhibition of expression of the target gene in a tissue-specific and/or temporally specific manner by placing expression of the polymerase under the control of an appropriately regulated promoter.

Introduction of DNA into nematodes in accordance with the method of the invention can be achieved using a variety of techniques, for example by direct injection into a body cavity or by soaking the worms in a solution containing the DNA. If the DNA is in the form of a vector as described herein, e.g. a plasmid harboring a cloned DNA fragment between two flanking T7 promoters, then dsRNA corresponding to this DNA fragment will be formed in the nematode resulting in down regulation of the corresponding gene. The

introduced DNA can form an extrachromosomal array, which array might result in a more catalytic knock-out or reduction of function phenotype. The DNA might also become integrated into the genome of the nematode, resulting in the same catalytic knock out or reduction of function phenotype, but which is stably transmittable.

In each aspect of the invention, the double-stranded RNA structure may be formed by two separate complementary RNA strands or a single self-complementary strand, as described above. Inhibition of target gene expression is sequence-specific in that only nucleotide sequences corresponding to the duplex region of the dsRNA structure are targeted for inhibition.

It is preferred to use dsRNA comprising a nucleotide sequence identical to a portion of the target gene, although RNA sequences with minor variations such as insertions, deletions and single base substitutions may also be used and are effective for inhibition. It will be readily apparent that 100% sequence identity between the dsRNA and a portion of the target gene is not absolutely required for inhibition and the phrase "substantially identical" as used herein is to be interpreted accordingly. Generally sequences which are substantially identical will share at least 90%, preferably at least 95% and more preferably at least 98% nucleic acid sequence identity. Sequence identity may be conveniently calculated based on an optimal alignment, for example using the BLAST program accessible at WWW.ncbi.nlm.nih.gov.

The invention will be further understood with reference to the following non-limiting Examples, together with the accompanying Figures in which:

Figure 1 is a plasmid map of the vector pGN1

containing opposable T7 promoters flanking a multiple cloning site and an ampicillin resistance marker.

5 Figure 2 is a plasmid map of the vector pGN8 (a genomic fragment of the *C. elegans unc-22* gene cloned in pGN1).

10 Figure 3 is a plasmid map of the vector pGN29 containing two T7 promoters and two T7 terminators flanking *Bst*XI sites. This vector permits cloning of DNA fragments linked to *Bst*XI adaptors.

15 Figure 4 is a plasmid map of the vector pGN39 containing two T7 promoters and two T7 terminators flanking attR recombination sites (based on the Gateway™ cloning system of Life Technologies, Inc).

20 Figure 5 is a plasmid map of the vector pGX22 (a fragment of the *C. elegans* gene C04H5.6 cloned in pGN29).

25 Figure 6 is a plasmid map of the vector pGX52 (a fragment of the *C. elegans* gene K11D9.2b cloned in pGN29).

Figure 7 is a plasmid map of the vector pGX104 (a fragment of the *C. elegans* gene Y57G11C.15 cloned in pGN29).

30 Figure 8 is a plasmid map of the vector pGZ8 (a fragment of the *C. elegans* gene T25G3.2 cloned in pGN39).

35 Figure 9 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in liquid culture were fed with *E. coli* containing the

plasmid pGX22.

Figure 10 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in
5 liquid culture were fed with *E. coli* containing the plasmid pGX52.

Figure 11 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in
10 liquid culture were fed with *E. coli* containing the plasmid pGXGZ8.

Figure 12 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in
15 liquid culture were fed with *E. coli* containing the plasmid pGX104

20

Example 1

Influence of genetic background on the efficiency of RNAi in *C. elegans*.

5 Introduction

Various different *C. elegans* strains were fed with different bacteria, to test the possibility of RNAi by feeding *C. elegans* with bacteria that produce dsRNA. The possibility of DNA delivery and dsRNA delivery has
10 previously been envisaged by using different bacterial strains. In this experiment the importance of the *C. elegans* strain as receptor of the dsRNA is also shown.

For this experiment the following *E. coli* strains were
15 used:

1. MC1061: F-*araD139* Δ (*ara-leu*)7696 *galE15 galK16*
 Δ (*lac*)X74 *rps1* (*Str^r*) *hsdR2* (*r_k⁻ m_k⁺*) *mcrA mcrB1*
- regular host for various plasmids,
20 - Wertman et al., (1986) Gene 49:253-262,
- Raleigh et al., (1989) in Current Protocols in Molecular Biology eds. Ausubel et al, Publishing associates and Wiley Interscience; New York. Unit 1.4.
- 25 2. B21(DE3): F- *ompT(lon)* *hsdS_B* (*r_B⁻, m_B⁻*; an *E. coli* B strain) with DE3, a λ prophage carrying the T7 RNA polymerase gene.
- regular host for IPTG inducible T7 polymerase
30 expression,
- Studier et al. (1990) Meth. Enzymol. 185:60-89
3. HT115 (DE3): F- *mcrA mcrb* IN(*rrnD-rrnE*) 1 λ -
rnc14::tr10 (DE3 lysogen: *lacUV5*
35 promoter-T7polymerase)
- host for IPTG inducible T7 polymerase

expression,
- RNaseIII-,
- Fire A, Carnegie Institution, Baltimore, MD,
Pers. Comm.

5

For this experiment the following *C. elegans* strains were used:

1. *C. elegans* N2: regular WT laboratory strain
2. *C. elegans* *nuc-1*(el393): *C. elegans* strain with a reduced endonuclease activity (>95%); condensed chromatin persists after programmed cell death; ingested (bacterial) DNA in the intestinal lumen is not degraded. Several alleles are described:
el392 (strong allele: has been used for the experiments described below); n887 (resembles el392) and n334 (weaker allele)
- Stanfield et al. (1998) East Coast Worm meeting abstract 171,
- Anonymous, Worm Breeder's Gazette 1(1):17b
Hevelone et al. (1988) Biochem. Genet. 26:447-461
- Ellis et al., Worm breeder's Gazette 7(2):44
- Babu, Worm Breeder's gazette 1(2):10
- Driscoll, (1996) Brain Pathol. 6:411-425
- Ellis et al., (1991) Genetics 129:79-94

For this experiment the following plasmids were used:

- pGN1: A vector encoding for ampicillin resistance, harbouring a multiple cloning site between two convergent T7 promoters.
- pGN8: pGN1 containing a genomic fragment of *unc-22*.
Decreased *unc-22* expression via RNAi results in a "twitching" phenotype in *C. elegans*.

Experimental conditions

- 12-well micro-titer plates were filled with approximately 2 ml of NGM agar per well (1 litre of NGM agar: 15g Agar, 1g peptone, 3g NaCl, 1ml cholesterol solution (5 mg/ml in EtOH), with sterile addition after autoclaving of 9.5 ml 0.1M CaCl₂, 9.5 ml 0.1 ml MgSO₄, 25 ml 1M KH₂PO₄/K₂HPO₄ buffer pH 6 and 5 ml nystatin solution (dissolved 10 mg/ml in 1:1 EtOH:CH₃COONH₄ 7.5 M).
- 10 The dried plates were spotted with approximately 50 µl of an overnight culture of bacteria. When IPTG induction was required, 50 µl of a 10 mM stock solution of IPTG was dropped on top of the bacteria lawn, and incubated at 37°C for approximately 4 hours.
- 15 Individual nematodes at the L4 growth stage were then placed in single wells. In each well 4 nematodes, and the plates were further incubated at 20°C for 6 days to allow offspring to be formed. The F1 offspring of
- 20 the seeded nematodes were tested for the twitching phenotype.

Results

Table 1: Percentage of the offspring that show the twitching phenotype

5	MC1061	N2	<i>nuc-1</i>
	pGN1	0%	0%
	pGN1 + IPTG	0%	0%
	pGN8	0%	0%
	pGN8 + IPTG	0%	0%
10	BL21 (DE3)		
	pGN1	0%	0%
	pGN1 + IPTG	0%	0%
	pGN8	20% (+)	>90% (++)
	pGN8 + IPTG	20% (+)	>90% (++±)
15	HT115 (DE3)		
	pGN1	0%	0%
	pGN1 + IPTG	0%	0%
	pGN8	50% (±)	>90% (++)
20	pGN8 + IPTG	80% (++)	>90% (++++)

5 %: percentage twitchers

 +: weak twitching

 ++: twitching

 +++: strong twitching

25

Conclusions

The experiment with *E. coli* MC1061 shows that no twitching could be observed in this experiment.

30 Neither the N2 nematodes nor the *nuc-1* nematodes showed any twitchers. This is to be expected as *E. coli* MC1061 does not produce any T7 RNA polymerase, and hence the unc-22 fragment cloned in pGN8 is not

expressed as dsRNA.

The experiment with *E. coli* strain BL21(DE3) and nematode strain N2 shows expected results. BL21(DE3) harbouring plasmid pGN1 does not result in any twitching as the pGN1 vector is an empty vector. BL21(DE3) harbouring PGN8 results in the expression of unc-22 dsRNA. When this dsRNA is fed to the N2 nematode (indirectly by feeding with the bacteria that produce the dsRNA), this results in a twitching phenotype, indicating that the dsRNA is able to pass the gut barrier and is able to perform its interfering activity.

Surprisingly the RNAi effect of the unc-22 dsRNA was even more pronounced in *C. elegans* strain *nuc-1* than in the wild type N2 strain. Although one may expect that the *nuc-1* mutation results in the non-degradation or at least in a slower degradation of DNA, as the NUC-1 protein is known to be involved in DNase activity, we clearly observe an enhancement of the RNAi induced phenotype in *C. elegans* with a *nuc-1* background. The *nuc-1* mutation has not been cloned yet, but it has been described that the gene is involved in nuclease activity, and more particularly DNase activity. If the NUC-1 protein is a nuclease, it may also have activity on nuclease activity on dsRNA, which would explain the enhanced RNAi phenotype. The *nuc-1* gene product may be a nuclease, or a regulator of nuclease activity. As the mode of action of RNAi is still not understood, it is also possible that the NUC-1 protein is interfering in the mode of action of RNAi. This would explain why a *nuc-1* mutant is more sensitive to RNAi.

The experiment with the *E. coli* strain HT115 (DE3)

confirms the experiments with the BL21(DE3) strain.
The RNA interference observed with the unc-22 dsRNA is
even higher. In comparison with strain BL21(DE3) this
could be expected, as HT115(DE3) is a RNase III minus
5 strain, and hence is expected to produce larger
amounts of dsRNA, resulting in more prominent RNAi.
This indicates further that the RNAi observed in this
experiment is the result of the dsRNA produced by the
bacteria fed to the *C. elegans*. Feeding *C. elegans*
10 *nuc-1* with HT115(DE3) harbouring pGN8 also results in
higher RNA interference phenotype than feeding the
same bacteria to *C. elegans* wild-type strain N2. Once
again this indicates that improved RNAi can realised
using a nuclease negative *C. elegans* and more
15 particularly with a with the *C. elegans nuc-1* (e1392)
strain.

Summary

RNA interference can be achieved in *C. elegans* by
20 feeding the worms with bacteria that produce dsRNA.
The efficiency of this RNA interference is dependent
both on the *E. coli* strain and on the genetic
background of the *C. elegans* strain. The higher the
level of dsRNA production in the *E. coli*, the more
25 RNAi is observed. This can be realised by using
efficient RNA expression systems such as T7 RNA
polymerase and RNAase negative strains, such as
RNaseIII minus stains. In this example the level of
dsRNA production varied: HT115(DE3)>BL21(DE3)>MC1061.

30 RNA interference is high in *C. elegans* strains that
are nuclease negative, or that are influenced in their
nuclease activity. This can be realised by using a
mutant strain such as *C. elegans nuc-1*.

35 In this example the sensitivity to RNAi varied:
C. elegans nuc-1 >> *C. elegans* N2

Example 2

Improved RNAi by feeding dsRNA producing bacteria in selected *C. elegans* strains-Comparison of the *nuc-1* strain with several mutants which show improved gut uptake (designated herein 'gun' mutants). Strains
5 bg77, bg78, bg83, bg84, bg85, bg86, bg87, bg88 and bg89 are typical gun mutant *C. elegans* strains isolated using selection for increased gut uptake (gun phenotype) with the marker dye BCECF-AM.

10

Experimental conditions:

- 12-well micro-titer plates were filled with approximately 2ml of NGM agar (containing 1ml/l of ampicillin (100µg/ml) and 5 ml of 100mM stock
15 IPTG) per well
- the dried plates were spotted with 25µl of an overnight culture of bacteria (BL21DE3/HT115DE3) containing the plasmids pGN1 (T7prom-T7prom) or pGN8 (T7prom-unc-22-T7prom)
- 20 - individual nematodes at the L4 growth stage were then placed in single wells, one nematode per well
- the plates were incubated at 20°C for 6 days to allow offspring to be formed
- 25 - the adult F1 offspring of the seeded nematodes were tested for the twitching phenotype

Results:

Table 2:

	20°C/6d	pGN1 HT115DE3	pGN8 BL2DE3	pGN8 HT115DE3	
5	N2	0	1	1	
	<i>nuc-1</i>	0	1-2	3	
	<i>bg77</i>	0	1-2	3	
	<i>bg78</i>	0	1	1-2	
	<i>bg83</i>	0	1	1	
10	<i>bg84</i>	0	1-2	3	
	<i>bg85</i>	0	1	2-3	
	<i>bg86</i>	0	1	2	
	<i>bg87</i>	0	1	1	
	<i>bg88</i>	0	1	1	
15	<i>bg89</i>	0	1	1	

figure legend:

0 = no twitching

20 1 = no to weak phenotype

2 = clear phenotype

3 = strong phenotype

25 **Conclusions**

- bacterial strain HT115(DE3) shows a better RNAi sensitivity than bacterial strain BL21(DE3)
- the *nuc-1* *C. elegans* strain is a better strain than the Wild-type N2 strain for RNAi sensitivity
- 30 - various gun mutants (improved gut uptake mutants) and more particularly the gun mutant strains *bg77*, *bg84*, *bg85*, *bg86* show improved sensitivity to RNAi compared to Wild-type.

A double mutant *C. elegans* strain (nuc-1/gun) shows even greater sensitivity to RNAi compared to wild-type:

5 Double mutants were constructed to test the prediction
that gun/nuc mutants would even show more enhanced
RNAi sensitivity. As an example, the crossing
strategy with gun strain bg85 is shown, similar
crosses can be conducted with other gun strains, such
10 as bg77, bg84 and bg86.

P0 cross: gun(bg85) x WT males

15 F1 cross: nuc-1 x gun(bg85)/+ males

F2 cross: nuc-1 x gun(bg85)/+; nuc-1/0 males (50%)
nuc-1 x +/+; nuc-1/0 males (50%)

20 F3 single: gun(bg85)/+; nuc-1 hermaphrodites (25%)
+/+; nuc-1 hermaphrodites (75%)

F4 single: gun(bg85); nuc-1 (1/4 of every 4th
plate high staining with BCECF)

25 F5 retest: gun(bg85); nuc-1 (100% progeny of F4
singled high staining with BCECF)

To select for the gun phenotype, the fluorescence
precursor BCECF-AM is used (obtainable from Molecular
30 probes). The precursor BCECF-AM is cleaved by
esterases present in the gut of the worm to generate
the dye BCECF which is fluorescent at pH values above
6. This allows selection for worms that have a gun
phenotype. BCECF-AM is taken up through the pharynx
35 into the gut lumen and is not fluorescent until it has
been cleaved, and the BCECF portion has entered the

cells surrounding the lumen. Wild-type worms will show slower or no increase in BCECF fluorescence.

5 **Example 3**

Improved RNAi feeding in liquid culture using *nuc-1*(el393) *C. elegans*.

Introduction

10 N2 and *nuc-1* *C.elegans* strains were fed with bacteria producing dsRNAs that give lethal phenotypes via RNAi. For this example RNAi was performed in liquid culture instead of on agar plates. We show here for a number of genes that the RNAi effect is more penetrant using
15 the *nuc-1* strain than the N2 strain, and that RNAi can be performed in liquid.

For this experiment the following *E.coli* strains were used:

20

1. HT115 (DE3): F- *mcrA mcrb* *IN(rrnD-rrnE)* 1 λ -
 rnc14::tr10 (DE3 lysogen: lacUV5 promoter -T7 polymerase)
 - host for IPTG inducible T7 polymerase expression
25 - RNaseIII⁻
 - Fire A, Carnegie Institution, Baltimore, MD, Pers. Comm.

25

For this experiment, following *C. elegans* strains were used:

30

1. *C. elegans* N2: regular WT laboratory strain
2. *C. elegans nuc-1*(el393): *C. elegans* strain with a
35 reduced endonuclease activity (>95%); condensed chromatin persists after programmed cell death;

35

- 5 ingested (bacterial) DNA in the intestinal lumen
is not degraded. Several alleles are described:
e1392 (strong allele: has been used for the
experiments described below); n887 (resembles
e1392) and n334 (weaker allele)
- Stanfield et al. (1998) East Coast Worm meeting
abstract 171
 - Anonymous, Worm Breeder's Gazette 1(1):17b
 - Hevelone et al. (1988) Biochem. Genet. 26:447-461
 - 10 - Ellis et al., Worm breeder's Gazette 7(2):44
 - Babu, Worm Breeder's gazette 1(2):10
 - Driscoll, (1996) Brain Pathol. 6:411-425
 - Ellis et al., (1991) Genetics 129:79-94

15

For this experiment, the following plasmids that all
give lethal phenotypes in *C. elegans* via RNAi were
used:

- 20 pGX22: a vector encoding ampicillin resistance,
containing a genomic fragment of cosmid C04H5.6
corresponding to a member of the RNA helicase family.

- 25 pGX52: a vector encoding ampicillin resistance,
containing a genomic fragment of cosmid K11D9.2b
corresponding to sarco/endoplasmic Ca²⁺ ATPase also
known as SERCA.

- 30 pGZ18: a vector encoding ampicillin resistance,
containing a genomic fragment of cosmid T25G3.2
corresponding to a chitin like synthase gene.

- 35 pGX104: a vector encoding ampicillin resistance,
containing a genomic fragment of cosmid Y57G11C.15
corresponding to sec-61, a transport protein.

Experimental conditions

- 1 ml overnight cultures of HT115 (DE3) bacteria containing the plasmids pGX22, pGX52, pGZ18 or pGX104 respectively were pelleted and resuspended in S-complete medium, containing 1ml/l of ampicillin (100 µg/ml) and 1ml/l of 1000mM IPTG.
- 10 µl of this bacterial solution was transferred to a 96-well microtiter plate already filled with 100 µl S-complete containing 1ml/l of ampicillin (100 µg/ml) and 1ml/l of 1000mM IPTG.
- 3 nematodes at the L1 growth stage of N2 and nuc-1 strain were then placed in single wells, 3 L1's per well. Per experimental set up, 16 wells were used (n=16).
- the plates were incubated at 25°C for 5 days to allow offspring to be formed.
- the plates were visually checked and the following phenotypes could be scored per individual well:
 - no effect:** L1's developed to adults and gave normal offspring.
 - no F1 offspring:** L1's developed to adults and gave no offspring.
 - acute lethal:** original L1 did not mature and died.

Results

- The results of this experiment are illustrated graphically in Figures 9 to 12. Data are expressed as

a percentage of the total (n=16) on the y-axis for both N2 and *nuc-1* strains.

Conclusions

5 The following genes were tested in this liquid RNAi assay:

- C04H5.6: an RNA helicase. RNAi of this gene interferes with the generation of offspring.
- 10 - SERCA: a sarco/endoplasmic Ca^{2+} ATPase. A strong RNAi phenotype causes an acute lethal phenotype. A less penetrant RNAi effect results in loss of offspring.
- T25G3.2: a chitin like synthase gene. RNAi of
15 this gene causes dead eggs.
- *sec-61*: a transport protein. A strong RNAi phenotype causes an acute lethal phenotype. A less penetrant RNAi effect results in loss of offspring.
- 20 - RNAi can be performed under liquid conditions.

As in the previous examples this set of experiments shows that the *nuc-1 C. elegans* strain is more sensitive to RNAi than the wild-type N2 strain. This
25 is most clear for less penetrant phenotypes such as SERCA and chitin synthase. For strong RNAi phenotypes like the helicase and *Sec-61* the difference between the N2 wild-type strain and the *nuc-1* stain is less pronounced.

Example 4**Cloning of pGX22, pGX52, pGZ18 and pGX104 for RNAi**

A set of primers for each gene was designed on the basis of sequence data available in the publicly accessible *C. elegans* sequence database (Acedb).

The cosmid names relate to:

1. **C04H5.6**=member of RNA helicase
2. **K11D9.2b**=SERCA
3. **Y57G11C.15**=transport protein sec-61
4. **T25G3.2**=chitin synthase like

The following primer sequences were designed:

1. **C04H5.6F** 5'-TGCTCAGAGAGTTTCTCAACGAACC-3'
C04H5.6R 5'-CAATGTTAGTTGCTAGGACCACCTG-3'
2. **K11D9.2bF** 5'-CAGCCGATCTCCGTCTTGTG-3'
K11D9.2bR 5'-CCGAGGGCAAGACAACGAAG-3'
3. **Y57G11C.15F** 5'-ACCGTGGTACTCTTATGGAGCTCG-3'
Y57G11C.15R 5'-TGCAGTGGATTGGGTCTTCG-3'
4. **T25G3.2F**
5'-GGGGACAAGTTTGTACAAAAAAGCAGGCTATGCCAAGTACATGTCGATTGCG-3'
T25G3.2R
5'-GGGGACCACTTTGTACAAGAAAGCTGGGTGGAGAAGCATTCGAGAGTTTG-3'

PCR was performed on genomic DNA of N2 strain *C. elegans* to give PCR products of the following sizes:

- 1326bp for C04H5.6
- 1213bp for K11D9.2b

1024bp for Y57G11C.15

1115bp for T25G3.2

5 The PCR fragments of C04H5.6, K11D9.2b and Y57G11C.15
were linked to *Bst*XI adaptors (Invitrogen) and then
cloned into the pGN29 vector cut with *Bst*XI. pGN29
contains two T7 promoters and two T7 terminators
flanking a cloning site which is adapted for
10 facilitated cloning of PCR fragments, comprising a
stuffer DNA flanked by two *Bst*XI sites (see schematic
Figure 3). The resulting plasmids were designated
pGX22 (C04H5.6), pGX52 (K11D9.2b) and pGX104
(Y57G11C.15).

15 The PCR fragment of T25G3.2 was cloned into pGN39 via
recombination sites based on the GATEWAY™ cloning
system (Life Technologies, Inc). pGN39 contains two
T7 promoters and two T7 terminators flanking a cloning
site which facilitates "High Throughput" cloning based
20 on homologous recombination rather than restriction
enzyme digestion and ligation. As shown schematically
in Figure 4, the cloning site comprises *att*R1 and
*att*R2 recombination sites from bacteriophage lambda
flanking a gene which is lethal to *E. coli*, in this
25 case the *ccdB* gene. This cloning site is derived from
the Gateway™ cloning system commercially available
from Life Technologies, Inc. The Gateway™ cloning
system has been extensively described by Hartley et
al. in WO 96/40724 (PCT/US96/10082).

30

Example 5

Selecting *C. elegans* mutations for increased gut uptake (gun) using marker dye BCECF-AM and *unc-31* as background.

5

The screen was performed in *unc-31(e928)* mutant background, to ensure high amounts of dye in the gut lumen, since *unc-31* mutations show constitutive pharyngeal pumping. The dye (BCECF-AM: 2',7' bis (2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxymethylester), obtained from Molecular Probes, is cleaved by intracellular esterases. Fluorescence accumulates in the gut cells upon passage through the apical gut membrane.

15

Mutagenesis

Day 1: *unc-31* L4 staged worms were mutagenised with EMS (final concentration 50 mM) for 4 hours

Day 2: P0 was divided over several large agar plates

Day 6: F1's were collected and dropped on large plates. The number of eggs the F1's laid were checked every hour and the F1's were removed when 10-20 eggs per F1 were counted

Day 10: F2 adults were collected and screened with BCECF-AM. Mutations with increased staining of the gut cells after 15-30 minutes exposure to the dye were selected and singled on small agar plates.

30

About 50 initial positives gave progeny which was retested with BCECF-AM (2x) and leucine CMB (1x) 9 of the 50 strains were kept (2 strains : 3 times positive, 7 other strains : twice positive)

35

Table 3: Isolation of mutations for increased staining with BCECF-AM

	Total P0	Total F1	Total F2	screened chromosomes	number of strains isolated
5	(counted)	(estimated)	(calculated)	(estimated)	(counted)
	2251	55618	222472	100000	9

Outcrossing, backcrossing and double construction

- 10 1. backcrossing *unc-31; gun* --> *unc-31; gun*
 - *unc-31; gun* x WT males
 - singled 2x5 WT hermaphrodites F1s (*unc-31/+;gun/+*)
 - singled 50 WT hermaphrodites F2s (1/4 homozygous)
 - select strains segregating 1/4 *unc*
- 15 - stain *unc* strains with BCECF-AM
 - from positive strains pick *unc* homozygous
 - retest 100 % *unc* strains with BCECF-AM
 - kept 1 strain (backcrossed)
- 20 2. *unc-31* background was crossed out-->+; *gun*
 - *unc-31; gun* x WT males
 - singled 2x5 WT hermaphrodites F1s (*unc-31/+;gun/+*)
 - singled 50 WT hermaphrodites F2s (1/4 homozygous)
 - select strains which did not segregate *unc* F3s
- 25 anymore
 - stain non *unc* strains with BCECF-AM
 - 7 positive strains were retested with BCECF-AM and finally 1 was selected and kept (outcrossed)
- 30 3. +; *gun* (1x outcrossed) were 2 times backcrossed-->+; *gun* (3x backcrossed)
 - *gun* x WT males
 - WT hermaphrodites x F1 males (*gun/+*)
 - singled 10 WT hermaphrodites F2s (1/2 heterozygous)
- 35 - singled 50 WT hermaphrodites F3s (1/8 homozygous)

- 31 -

- stain strains with BCECF-AM- retested positives with BCECF-AM and finally 1 was selected and kept

4. *gun* (3x backcrossed) were crossed with *nuc-1*(X)
 5 mutant--> *gun*; *nuc-1*
 - *gun* x WT males
 - *nuc-1* x *gun*/+ males
 - *nuc-1* x *gun*/+; *nuc-1*/0 or +/+; *nuc-1*/0 males
 - singled 10 WT hermaphrodite progeny (*nuc-1*
 10 homozygous, ½ heterozygous *gun*)
 - singled 40 WT hermaphrodite progeny (1/8 homozygous *gun*)
 - stain strains with BCECF-AM
 - retested positives with BCECF-AM and finally 1 was
 15 selected and kept

Table 6: Strains derived from *gun* mutations

20	<i>gun</i>	<i>unc-31</i> ; <i>gun</i>		<i>unc-31</i> ; <i>gun</i>		+; <i>gun</i>		<i>gun</i> ; <i>nuc-1</i>
		original isolate		backcrossed (1x)		outcrossed (1x)	3x b.c.	from 3x b.c.
	allele number	isolation number	strain number	isolation number	strain number	isolation number	strain number	strain number
	bg77	31.4	UG 510	31.4.46.1	UG 556	31.4.34	UG 563	UG 674
25	bg78	37.5	UG 511	37.5.46.4	UG 557	37.5.15	UG 564	UG 675
	bg83	10.2	UG 543	10.2.11	UG 600	10.2.21	UG 586	UG 676
	bg84	7.2	UG 544	7.2.10	UG 601	7.2.15	UG 589	UG 677
	bg85	11.5	UG 545	11.5.29.2	UG 602	2x b.c.	UG 717	UG 775
	bg86	42.1	UG 546	42.1.4.5	UG 603	42.1.18	UG 587	UG 678
30	bg87	7.1	UG 547	7.1.8.3	UG 604	7.1.22	UG 585	UG 679
	bg88	5.3	UG 548	5.3.9	UG 605	5.3.18	UG 584	UG 680
	bg89	23.4	UG 549	23.4.13.5	UG 606	23.4.3	UG 588	UG 671

SEQUENCE LISTING:

SEQ ID NO: 1 complete sequence of pGN1

5 SEQ ID NO: 2 complete sequence of pGN8

SEQ ID NO: 3 complete sequence of pGN29

SEQ ID NO: 4 complete sequence of pGN39

10 SEQ ID NO: 5 complete sequence of pGX22

SEQ ID NO: 6 complete sequence of pGX52

15 SEQ ID NO: 7 complete sequence of pGX104

SEQ ID NO: 8 complete sequence of pGZ8

SEQ ID NO: 9 primer C04H5.6F

20 SEQ ID NO: 10 primer C04H5.6R

SEQ ID NO: 11 primer K11D9.2bF

25 SEQ ID NO: 12 primer K11D9.2bR

SEQ ID NO: 13 primer Y57G11C.15F

SEQ ID NO: 14 primer Y57G11C.15R

30 SEQ ID NO: 15 primer T25G3.2F

SEQ ID NO: 16 primer T25G3.2R

Claims:

1. A method of inhibiting expression of a target gene in a nematode worm comprising feeding to
5 said nematode worm a food organism which is capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the nematode
10 has a non wild-type genetic background selected to provide increased sensitivity to RNA interference as compared to wild type.
2. A method as claimed in claim 1 wherein the
15 nematode is a microscopic nematode.
3. A method as claimed in claim 2 wherein the nematode is from the genus *Caenorhabditis*.
- 20 4. A method as claimed in claim 3 wherein the nematode is *C. elegans*.
5. A method as claimed in any one of claims 1 to 4 wherein the nematode has a mutant genetic
25 background.
6. A method as claimed in claim 5 wherein the nematode is a mutant strain which exhibits reduced activity of one or more nucleases compared to wild
30 type.
7. A method as claimed in claim 6 wherein the nematode is *C. elegans* strain *nuc-1*.
- 35 8. A method as claimed in claim 5 wherein the nematode is a mutant strain which exhibits increased

gut uptake compared to wild type.

9. A method as claimed in claim 8 wherein the nematode is mutant *C. elegans* strain bg85.

5

10. A method as claimed in claim 5 wherein the nematode is a mutant strain having at least one mutation which results in reduced nuclease activity compared to wild type and at least one mutation which results in increased gut uptake compared to wild type.

10

11. A method as claimed in claim 10 wherein the nematode is a mutant *C. elegans* strain having the *nuc-1* mutation and the bg85 mutation.

15

12. A method as claimed in any one of the preceding claims wherein the food organism has been engineered to express a double-stranded RNA.

20

13. A method as claimed in any one of the preceding claims wherein the food organism is a bacterium.

25

14. A method as claimed in claim 13 wherein the food organism is *E. coli*.

30

15. A method as claimed in any one of the preceding claims wherein the food organism has been genetically modified to express a double-stranded RNA having a nucleotide sequence substantially identical to a portion of said target gene.

35

16. A method as claimed in claim 15 wherein the food organism contains a DNA vector, the vector comprising a promoter or promoters orientated relative to a DNA sequence such that they are capable of

initiating transcription of said DNA sequence to RNA capable of forming a double-stranded structure upon binding of an appropriate RNA polymerase to said promoter or promoters.

5

17. A method as claimed in claim 25 wherein the vector comprises two promoters flanking the DNA sequence.

10

18. A method as claimed in claim 26 wherein the two promoters are identical.

15

19. A method as claimed in claim 25 wherein the vector comprises a single promoter and further comprises said DNA sequence in a sense and an antisense orientation relative to said promoter.

20

20. A method as claimed in any one of claims 16 to 20 wherein the nematode or the food organism is adapted to express an RNA polymerase capable of initiating transcription from said promoter or promoters.

25

21. A method as claimed in any one of claims 16 to 20 wherein the RNA polymerase is T7, T3 or SP6 polymerase.

30

22. A method as claimed in any one of claims 1 to 21 wherein the step of feeding said food organism to said nematode worm is carried out in liquid culture.

35

23. A method of inhibiting expression of a target gene in a nematode worm comprising feeding to said nematode worm a food organism capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a

portion of said target gene following ingestion of the food organism by the nematode, wherein the food organism carries a modification selected to provide increased expression or persistence of the doubled-stranded RNA compared to a food organism which does not carry the modification.

24. A method as claimed in claim 23 wherein the food organism is a bacterium.

25. A method as claimed in claim 24 wherein the bacterium is an *E. coli* strain.

26. A method as claimed in claim 25 wherein the *E. coli* strain is an RNase III minus strain or any other RNase negative strain.

27. A method as claimed in any one of claims 23 to 26 wherein the step of feeding said food organism to said nematode worm is carried out in liquid culture.

28. A method of inhibiting expression of a target gene in a nematode worm comprising introduction of a DNA capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene in said nematode, wherein the nematode is one which exhibits increased gut uptake compared to wild type.

29. A method as claimed in claim 28 wherein the nematode is a microscopic nematode.

30. A method as claimed in claim 29 wherein the nematode is from the genus *Caenorhabditis*.

31. A method as claimed in claim 30 wherein the

nematode is *C. elegans*.

32. A method as claimed in any one of claims 28
to 31 wherein the nematode has a mutant genetic
5 background.

33. A method as claimed in claim 32 wherein the
nematode is mutant *C. elegans* strain bg85.

10 34. A method as claimed in any one of claims 28
to 33 wherein the DNA capable of producing a double-
stranded RNA structure is a vector comprising a
promoter or promoters orientated relative to a DNA
sequence such that they are capable of initiating
15 transcription of said DNA sequence to RNA capable of
forming a double-stranded structure upon binding of an
appropriate RNA polymerase to said promoter or
promoters.

20 35. A method as claimed in claim 34 wherein the
vector comprises two promoters flanking the DNA
sequence.

25 36. A method as claimed in claim 35 wherein the
two promoters are identical.

30 37. A method as claimed in claim 34 wherein the
vector comprises a single promoter and further
comprises said DNA sequence in a sense and an
antisense orientation relative to said promoter.

35 38. A method as claimed in any one of claims 34
to 37 wherein the nematode is adapted to express an
RNA polymerase capable of initiating transcription
from said promoter or promoters.

39. A method as claimed in any one of claims 34

to 38 wherein the RNA polymerase is T7, T3 or SP6 polymerase.

FIG. 1.




FIG. 2




FIG. 3.




FIG. 4.




FIG. 5.




FIG. 6.




FIG. 7.




FIG. 8.




FIG. 9.




FIG. 10.




FIG. 11.





FIG. 12.



1
SEQUENCE LISTING

<110> DEVGEN NV

<120> IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA INHIBITION

<130> SCB/53711/001

<140>

<141>

<160> 14

<170> PatentIn Ver. 2.0

<210> 1

<211> 3216

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGN1

<400> 1

gagtgaccca	tatgcggtgt	gaaataccgc	acagatgcgt	aaggagaaaa	taccgcatca	60
ggcgaaattg	taaacgttaa	tattttgtta	aaattcgcgt	taaatatttg	ttaaatcagc	120
tcatttttta	accaataggc	cgaaatcggc	aaaatccctt	ataaatcaaa	agaatagacc	180
gagataggg	tgagtgtgt	tccagtttgg	aacaagagtc	cactattaaa	gaacgtggac	240
tccaacgtca	aagggcgaaa	aaccgtctat	cagggcgatg	gccactacg	tgaaccatca	300
cccaaataca	gttttttgcg	gtcgaggtgc	cgtaaagctc	taaatcgga	ccctaaaggg	360
agccccgat	ttagagcttg	acggggaaag	ccggcgaaac	tggcgagaaa	ggaaggggaag	420
aaagcgaaag	gagcggggcg	tagggcgctg	gcaagtgtag	cggtcacgct	gcgcgtaacc	480
accacacccg	ccgcgcttaa	tgcgccgcta	cagggcgctg	ccattcgcca	ttcaggctgc	540
gcaactgttg	ggaagggcga	tcggtgcggg	cctcttcgct	attacgccag	ctggcgaaaag	600
ggggatgtgc	tgcaaggcga	ttaagttggg	taacgccagg	gttttcccag	tcacgacgtt	660
gtaaaacgac	ggccagtga	ttgtaatacg	actcactata	gggcgaattc	gagctcggtg	720
cccggggatc	ctctagagtc	gaaagcttct	cgccctatag	tgagtcgtat	tacagcttga	780
gtattctata	gtgtcaccta	aatagcttgg	cgtaatcatg	gtcatagctg	tttcctgtgt	840
gaaattgtta	tccgctcaca	attccacaca	acatacagac	cggaagcata	aagtgtaaag	900
cctgggtgct	ctaatagtg	agctaactca	cattaattgc	gttgcgctca	ctgcccgctt	960
tccagtcggg	aaacctgtcg	tgccagctgc	attaatgaat	cggccaacgc	gcggggagag	1020
gcggtttgcg	tattgggcgc	tcttccgctt	cctcgctcac	tgactcgctg	cgctcggtcg	1080
ttcggctgcg	gcgagcggtg	tcagctcact	caaaggcggg	aatacgggta	tccacagaat	1140
caggggataa	cgcaggaaaag	aacatgtgag	caaaaggcca	gcaaaaggcc	aggaaccgta	1200
aaaaggccgc	gttgctggcg	tttttcgata	ggctccgccc	ccctgacgag	catcacaaaa	1260
atcgacgctc	aagtcagagg	tggcgaaacc	cgacaggact	ataaagatac	caggcgtttc	1320
cccttgaag	ctccctcggtg	cgctctcctg	ttccgacctt	gocgcttacc	ggatacctgt	1380
ccgcctttct	cccttcggga	agcgtggcgc	tttctcatag	ctcacgctgt	aggtatctca	1440
gttcggtgta	ggtcgttcgc	tccaagctgg	gctgtgtgca	cgaaccccc	gttcagcccg	1500
accgctgcgc	cttatccggt	aactatcgct	ttgagtccaa	cccggtgaaga	cacgacttat	1560
cgccactggc	agcagccact	ggtaacagga	ttagcagagc	gaggtatgta	ggcgggtgcta	1620
cagagtctct	gaagtgggtg	cctaactacg	gctacactag	aaggacagta	tttggtatct	1680
gcgctctgct	gaagccagtt	accttcggaa	aaagagttgg	tagctcttga	tccggcaaac	1740
aaaccaccgc	tggtagcggg	ggtttttttg	tttgcaagca	gcagattacg	cgcagaaaaa	1800
aaggatctca	agaagatcct	ttgatctttt	ctacgggggc	tgacgctcag	tggacgaaa	1860
actcacgtta	agggattttg	gtcatgagat	tatcaaaaag	gatcttcacc	tagatccttt	1920
taaattaaaa	atgaagtttt	aaatcaatct	aaagtatata	tgagtaaact	tggtctgaca	1980

```

gttaccaatg cttaatcagt gaggcaccta tctcagcgat ctgtctatatt cgttcatcca 2040
tagttgcctg actccccgtc gtgtagataa ctacgatacg ggagggccta ccatctggcc 2100
ccagtgctgc aatgataccg cgagaccac gctcaccggc tccagattta tcagcaataa 2160
accagccagc cggaagggcc gagcgcagaa gtggctcctgc aactttatcc gcctccatcc 2220
agtctattaa ttgttgccgg gaagctagag taagtagttc gccagttaat agtttgcgca 2280
acgttgttgg cattgctaca ggcacgtgg tgtcacgctc gtcgtttggt atggcttcat 2340
tcagctccgg ttccaacga tcaaggcgag ttacatgatc ccccatgttg tgcaaaaaag 2400
cggttagctc cttcggctct ccgatcgttg tcagaagtaa gttggccgca gtgttatcac 2460
tcatggttat ggcagcactg cataattctc ttactgtcat gccatccgta agatgctttt 2520
ctgtgactgg tgagtactca accaagtcac tctgagaata ccgcgccgg cgaccgagtt 2580
gctcttgccc ggcgtcaata cgggataata tctgtatgaca tagcagaact ttaaaagtgc 2640
tcatcattgg aaaacgttct tcggggcgaa aactctcaag gatcttaccg ctgttgagat 2700
ccagttcgat gtaaccact cgtgcaccca actgatcttc agcatctttt actttcacca 2760
gcgtttctgg gtgagcaaaa acaggaaggc aaaatgccgc aaaaaaggga ataagggcga 2820
cacggaaatg ttgaatactc atactcttcc tttttcaata ttattgaagc atttatcagg 2880
gttattgtct catgagcgga tacatatttg aatgtattta gaaaaataaa caaatagggg 2940
ttccgcgcac atttccccga aaagtgccac ctgacgtcta agaaaccatt atttatcatga 3000
cattaaccta taaaaatagg cgtatcacga ggccctttcg tctcgcgcgt ttcgggtgatg 3060
acggtgaaaa cctctgacac atgcagctcc cggagacggg cacagcttgt ctgtaagcgg 3120
atgccgggag cagacaagcc cgtcagggcg cgtcagcggg tgttgggcggg tgtcggggct 3180
ggcttaacta tgcggcatca gagcagattg tactga 3216

```

<210> 2

<211> 4620

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGN8

<400> 2

```

gatccgaatc tccatgtctg ttaacagcct tgacacggaa tttatattca tgcccttgag 60
tcaaatcgtc aacgtggaag ttggtatcct tgctctctcc gcaagcagtc catctgccag 120
tggcagcatc ttgcttttca atgacatagt gactgatttc agctcctcca tcatcttctg 180
gttccttcca tgcaagatca catccatcct tgacaatatt agtgacatcg agaggtccac 240
gtgggcttga tggatgatca agaacagtaa ccttcacttc agcagtgtca gttccattct 300
cgttctctgc cttgatgata taggttcctg tatccgaacg caaagctctc ttcacatgga 360
atttagtctt gccgtcttca ttgttcaact tcatacgatc atcagattcg actggtgttc 420
cttcgaaagt ccaagtaatt gttggaattg gttcaccact gactggaatg ttcaatgaga 480
agctctgtcc agccttgacc ttgatttctt gaatcgagtt acgatcgatg actggtggaa 540
ctataattta attcaatgat tattagtaat tgatttagac tcttaccatt tctagccttt 600
gcaacagctg atgctgaatc agatggatct cccaatcctg ccttggttctt ggcacggatt 660
ctgaattcgt actttgatcc ttccttgaga tttccaacag tagcattcgt ttgtccagct 720
ggaacatgag caacgtcatt ccagaatggc gagaactcgt ccttcatctc aacaacgtat 780
tcctcgattg gagcaccacc gtcgtttgct ggtggcttcc attcaaggtc aacatgatcc 840
ttatcccaat cagtaatttc aggagcattt gcttttctg gcttgtaaaa tggatctttg 900
gcaagtgtgg ttccgaaggt ctccaatgga tcggactctc cttcagcatt gacggcagcg 960
acacggaact gaaaatcaaa atgttgtagg caattgagtt caagattaaa aaattctcac 1020
tttatattca tgtccaggaa taagaccgtc aacaacagct gtagtcttat ctccagcgac 1080
ctttgcagct ggaacccatc ttccacttgc agtatcgtac ttttcgatca catagttttc 1140
aattggaata cctccatcat catctgggtc acgccaattc aaagtgcacat gatcaccatg 1200
aacatcgga aacatctaat gaccatttgg agaagttggc ttgtctgaaa atttaaaata 1260
taaccaaatt aattgaagaa aactaatgct caccaataac attgatctta acagttgctt 1320
catcttctcc atttgcattg acagctttga tagtgaaagt tccactgtct ccagtttcca 1380
tttgcttcac aaccagcttt gattgggtatt ctgggttatc aagcttctcg ccctatagt 1440
agtcgtatta cagcttgagt attctatagt gtcacataaa tagcttggcg taatcatggt 1500
catagctgtt tctgtgtga aattgttatc cgtcacaaat tccacacaac atacgagccg 1560
gaagcataaa gtgtaaagcc tgggggtgcct aatgagttag ctaactcaca ttaattgcgt 1620

```

tgcgctcact	gccccgctttc	cagtcgggaa	acctgtcgtg	ccagctgcat	taatgaatcg	1680
gccaacgcgc	ggggagaggg	ggtttgcgta	ttgggcgctc	ttccgcttcc	tcgctcactg	1740
actcgctgcg	ctcggtcggt	cggtgcggc	gagcggatc	agctcactca	aaggcggtaa	1800
tacggttatc	cacagaatca	ggggataacg	caggaaagaa	catgtgagca	aaaggccagc	1860
aaaaggccag	gaaccgtaaa	aaggccgcgt	tgctggcggt	tttcgatagg	ctccgcccc	1920
ctgacgagca	tcacaaaaat	cgacgctcaa	gtcagagggt	gcgaaacccg	acaggactat	1980
aaagatacca	ggcgtttccc	cctggaagct	ccctcggtcg	ctctcctggt	ccgaccctgc	2040
cgcttaccgg	atacctgtcc	gcctttctcc	cttcgggaag	cgtggcgctt	tctcatagct	2100
cacgctgtag	gtatctcagt	tcggtgtagg	tcgttcgctc	caagctgggc	tgtgtgcacg	2160
aaccccccg	tcagcccgac	cgctgcgcct	tatccggtaa	ctatcgtctt	gagtcgaacc	2220
cggtaagaca	cgacttatcg	ccactggcag	cagccactgg	taacaggatt	agcagagcga	2280
ggtatgtagg	cggtgtctaca	gagttcttga	agtgggtggc	taactacggc	tacactagaa	2340
ggacagtatt	tggatctctgc	gctctgctga	agccagttac	cttcgaaaaa	agagttggta	2400
gctcttgatc	cggcaaaaca	accaccgctg	gtagcgggtg	tttttttgtt	tgcaagcagc	2460
agattacgcg	cagaaaaaaa	ggatctcaag	aagatccttt	gatcttttct	acggggtctg	2520
acgctcagtg	gaacgaaaac	tcacgttaag	ggatttttgt	catgagatta	tcaaaaagga	2580
tcttcaccta	gatcctttta	aattaaaaat	gaagttttta	atcaatctaa	agtatatatg	2640
agtaaacttg	gtctgacagt	taccaatgct	taatcagtga	ggcacctatc	tcagcgatct	2700
gtctatcttc	ttcatccata	gttgccgtgac	tccccgctc	gtagataact	acgatacggg	2760
agggtttacc	atctggcccc	agtgtgcaa	tgtatccgcg	agaccacgc	tcaccggctc	2820
cagattttatc	agcaataaac	cagccagccg	gaagggccga	gcgcagaagt	ggtcctgcaa	2880
ctttatccgc	ctccatccag	tctattaatt	gttgccggga	agctagagta	agtagttcgc	2940
cagttaatag	tttgcgcaac	gttggtggca	ttgctacagg	catcgtgggt	tcacgctcgt	3000
cgtttggtat	ggcttcattc	agctccgggt	cccaacgatc	aaggcgagtt	acatgatccc	3060
ccatgttgtg	caaaaaagcg	gttagctcct	tcggtcctcc	gatcgttgtc	agaagtaagt	3120
tggccgcagt	gttatcactc	atggttatgg	cagcactgca	taattctctt	actgtcatgc	3180
catccgtaag	atgcttttct	gtgactgggt	agtactcaac	caagtcattc	tgagaatacc	3240
gcgcccggcg	accgagttgc	tcttgcccg	cgtcaatacg	ggataatagt	gtatgacata	3300
gcagaacttt	aaaagtgtc	atcattggaa	aacgttcttc	ggggcgaaaa	ctctcaagga	3360
tcttaccgct	gttgagatcc	agttcgatgt	aaccactcg	tgcacccaac	tgatcttcag	3420
catcttttac	tttcaccagc	gtttctgggt	gagcaaaaac	aggaaggcaa	aatgccgcaa	3480
aaaagggaat	aagggcgaca	cggaaatgtt	gaatactcat	actcttctct	tttcaatatt	3540
attgaagcat	ttatcagggg	tattgtctca	tgagcggata	catatttgaa	tgtatttaga	3600
aaaataaaca	aataggggtt	ccgcgcacat	ttccccgaaa	agtgccacct	gacgtctaag	3660
aaaccattat	tatcatgaca	ttaacctata	aaaataggcg	tatcacgagg	ccctttcgtc	3720
tcgcgcgttt	cgggtgatgac	ggtgaaaacc	tctgacacat	gcagctccc	gagacgggtc	3780
cagcttgtct	gtaagcggat	gccgggagca	gacaagccc	tcagggcgcg	tcagcgggtg	3840
ttggcgggtg	tcggggctgg	cttaactatg	cggcatcaga	gcagattgta	ctgagagtgc	3900
accatatgcg	gtgtgaaata	ccgcacagat	gcgtaaggag	aaaataccgc	atcaggcgaa	3960
attgtaaacg	ttaatatatt	gttaaaattc	gcgttaata	tttgttaaat	cagctcattt	4020
tttaaccaat	aggccgaaat	cggcaaaatc	ccttataaat	caaaagaata	gaccgagata	4080
gggttgagtg	ttgttccagt	ttggaacaag	agtccactat	taaagaacgt	ggactccaac	4140
gtcaaagggc	gaaaaaccgt	ctatcagggc	gatggcccac	tacgtgaacc	atcacccaaa	4200
tcaagttttt	tgcggtcgag	gtgccgtaaa	gctctaaatc	ggaaccctaa	agggagcccc	4260
cgatttagag	cttgacgggg	aaagccggcg	aacgtggcga	gaaaggaagg	gaagaaagcg	4320
aaaggagcgg	gcgctagggc	gctggcaagt	gtagcgggtc	cgctgcgcgt	aaccaccaca	4380
ccgcgcgcgc	ttaatgcgcc	gctacagggc	gcgtccattc	gccattcagg	ctgcgcaact	4440
gttgggaagg	gcgatcgggt	cgggcctctt	cgctattacg	ccagctggcg	aaagggggat	4500
gtgctgcaag	gcgattaagt	tgggtaacgc	cagggttttc	ccagtcacga	cgttgtaaaa	4560
cgacggccag	tgaattgtaa	tacgactcac	tatagggcga	attcgagctc	ggtacccggg	4620

<210> 3

<211> 4756

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGX22

<400> 3

tgctcagaga	gtttctcaac	gaacccgatt	tggctagtta	taggtaattt	ttagaacatt	60
tacaaaaaca	gcaaaaaaac	caaacattca	ggatttttgt	ttttaattaa	gaaaaaaatc	120
gatcgctcct	aaattttta	caatacttcg	aataaaccca	aaaaaaaacg	aaaaaaaatc	180
ctgtttccag	tgtaatgatg	attgacgagg	ctcacgaacg	tactctacac	acggatattc	240
tattcgggtt	agtcaaagat	attgcaagat	tccgaaagga	tttgaagcct	ctcatctcct	300
ctgcaacact	tgacgctgaa	aagtctctca	gtttcttcga	cgacgctccg	attttccgaa	360
tcgacggcgc	cagattcccg	gtggacattt	actatacaca	ggctcccga	gcggactacg	420
tgcagcggc	tatcgtcaca	attatgcaga	ttcacttgac	ccagccactt	cccggcgata	480
ttttggtatt	tctgactgg	caggaagaaa	tcgaaactgt	acaggaagca	cttatggaac	540
ggctcgaaagc	actgggatcg	aagattaagg	agcttattcc	gctgccgggt	tatgcgaatt	600
tgcccagtga	tttgcaggcg	aagattttcg	agccaacgcc	gaaagatgcy	agaaaggtag	660
atttttctta	caaatttttt	ccaaaaaaa	atccgagaaa	aatctacaaa	atttcaggca	720
aaaactgttt	cattttattc	ctaactagtt	ttttagcaaa	cgtttagatt	taacaaaact	780
gaacaaattt	gaagttttcc	aatttaaaaa	ataaatgttt	cggaaagtgt	attgaaaaat	840
ctgaaattgc	tatcctctcg	tatctgcaaa	aaaaacactt	taaaaaatgc	tctgttcttt	900
gaaaatttct	aaactgaaaa	atttgaaatt	tctgaaaatt	gtgataattt	tataaaattt	960
tatagaaaat	gtaagcattc	cagaaaaata	tcaaaaattt	cgagaaaatt	ctgaaaaaat	1020
ccagaaaat	taacagaaaa	aaaatctttt	gaaacatctg	aaaattaaaa	taaattgaat	1080
ttacattttt	ttttttggga	tttctttaa	atcactatga	atttaccact	aaattttttg	1140
caaaaaatta	ttttttta	ttcaaagaaa	aagcaaagaa	ttttaaaata	tcaaaaagtc	1200
caaatttggt	tcggtgaatt	tttaaaataa	cattttcaag	ataattttta	gttaatcaaa	1260
acattccacg	catttctagt	ttcccaaatt	tctctaaatt	tcaggtgggt	ctagcaacta	1320
acattgccag	cacaatggat	ctcgagggat	cttccatacc	taccagttct	gcgcctgcag	1380
gtcgcggccg	cgactctcta	gacgcgtaag	cttactagca	taacccttg	gggcctctaa	1440
acgggtcttg	aggggttttt	tgagcttctc	gccctatagt	gagtcgtatt	acagcttgag	1500
tattctatag	tgctaccta	atagcttgcc	gtaatcatgg	tcatagctgt	ttcctgtgtg	1560
aaattggtat	ccgctcacaa	ttccacacaa	catacgagcc	ggaagcataa	agtgtaaagc	1620
ctggggtgcc	taatgagtga	gctaaactac	attaattgcy	ttgcgctcac	tgcccgcttt	1680
ccagtcggga	aacctgtcgt	gccagctgca	ttaatgaatc	ggccaacgcg	cggggagagg	1740
cggtttgctg	attgggcgct	cttccgcttc	ctcgctcact	gactcgctgc	gctcggctcg	1800
tcggctgcgg	cgagcgggat	cagctcactc	aaaggcggta	atacggttat	ccacagaatc	1860
aggggataac	gcaggaaaag	acatgtgagc	aaaaggccag	caaaaggcca	ggaaccgtaa	1920
aaaggccgcg	ttgctggcgt	ttttcgatag	gctccgcccc	cctgacgagc	atcacaaaaa	1980
tcgacgctca	agtacagagt	ggcgaaaccc	gacaggacta	taaagatacc	aggcgtttcc	2040
ccctggaagc	tccctcgtgc	gctctcctgt	tccgaccctg	ccgcttaccg	gataacctgtc	2100
cgcttttctc	ccttcgggaa	gcgtggcgct	ttctcatagc	tcacgctgta	ggtatctcag	2160
ttcgggtgtag	gtcgttcgct	ccaagctggg	ctgtgtgcac	gaaccccccg	ttcagcccga	2220
ccgctgcgcc	ttatccggta	actatcgtct	tgagtccaac	ccggtaagac	acgacttatt	2280
gccactggca	gcagccactg	gtaacaggat	tagcagagcg	aggtagtag	gcggtgctac	2340
agagttcttg	aagtgttgcc	ctaactacgg	ctacactaga	aggacagtat	ttggtatctg	2400
cgctctgctg	aagccagtta	ccttcggaaa	aagagttggt	agctcttgat	ccggcaaaaa	2460
aaccaccgct	ggtagcgggt	gtttttttgt	ttgcaagcag	cagattacgc	gcagaaaaaa	2520
aggatctcaa	gaagatcctt	tgatcttttc	tacggggtct	gacgctcagt	ggaacgaaaa	2580
ctcacgttaa	gggatttttg	tcatgagatt	atcaaaaagg	atcttcacct	agatcctttt	2640
aaattaaaaa	tgaagtttta	aatcaatcta	aagtatatat	gagtaaaact	ggtctgacag	2700
ttaccaatgc	ttaatcagtg	aggcacctat	ctcagcgatc	tgtctatttc	gttcatccat	2760
agttgcctga	ctccccgtcg	tgtagataac	tacgatacgg	gagggcttac	catctggccc	2820
cagtgcctga	atgataccgc	gagaccacag	ctcaccggct	ccagatttat	cagcaataaa	2880
ccagccagcc	ggaaggccgc	agcgcagaag	tggtcctgca	actttatccg	cctccatcca	2940
gtctattaat	tgttgccggg	aagctagagt	aagtagttcg	ccagttaata	gtttgcgcaa	3000
cgttgttgcc	attgctacag	gcacgtgggt	gtcacgctcg	tcgtttggta	tggcttcatt	3060
cagctccggt	tcccaacgat	caaggcgagt	tacatgatcc	cccatgttgt	gcaaaaaagc	3120
ggttagctcc	ttcggctcct	cgatcggttg	cagaagtaag	ttggccgcag	tgttatcact	3180
catggttatg	gcagcactgc	ataattctct	tactgtcatg	ccatccgtaa	gatgcttttc	3240
tgtgactggt	gagtactcaa	ccaagtcatt	ctgagaatac	cgcgcccgcc	gaccgagttg	3300
ctcttgcccc	gcgtcaatac	gggataatag	tgtatgacat	agcagaactt	taaaagtgtc	3360

```

catcattgga aaacgttctt cggggcgaaa actctcaagg atcttaccgc tgttgagatc 3420
cagttcgaatg taaccactc gtgcacccaa ctgatcttca gcatctttta ctttcaccag 3480
cgtttctggg tgagcaaaaa caggaaaggca aaatgccgca aaaaaggga taaggcgac 3540
acggaaatgt tgaataactca tactcttcct ttttcaatat tattgaagca tttatcaggg 3600
ttattgtctc atgagcggat acatatttga atgtatttag aaaaataaac aaataggggt 3660
tccgcgcaca tttcccgaa aagtgccacc tgacgtctaa gaaaccatta ttatcatgac 3720
attaacctat aaaaataggc gtatcacgag gccctttcgt ctgcgcgctt tcggtgatga 3780
cggtgaaaac ctctgacaca tgcagctccc ggagacggtc acagcttgct tgtaagcgga 3840
tgccgggagc agacaagccc gtcagggcgc gtcagcgggt gttggcgggt gtcggggctg 3900
gcttaactat gcggcatcag agcagattgt actgagagt caccatatgc ggtgtgaaat 3960
accgcacaga tgcgtaagga gaaaataacc catcaggcga aattgtaaac gttaatattt 4020
tggtaaaaat cgcgttaaat atttgttaaa tcagctcatt ttttaaccaa taggccgaaa 4080
tcggcaaaat cccttataaa tcaaaagaat agaccgagat agggttgagt gttgttccag 4140
tttgaacaa gagtccacta ttaaagaacg tggactccaa cgtcaaagg cgaaaaaccg 4200
tctatcaggg cgatggccca ctacgtgaac catcaccaa atcaagtttt ttgcggtcga 4260
ggtgccgtaa agctctaaat cggaacccta aaggagccc ccgatttaga gcttgacggg 4320
gaaagccggc gaacgtggcg agaaaggaag ggaagaaagc gaaaggagcg ggcgctaggg 4380
cgctggcaag tgtagcggtc acgctgcgcg taaccaccac accgcgcgcg cttaatgcgc 4440
cgctacaggg cgcgtccatt cgccattcag gctgcgaac tgttggaag ggcgatcgg 4500
gcgggcctct tcgctattac gccagctggc gaaaggggga tgtgctgcaa ggcgattaag 4560
ttgggtaacg ccagggtttt ccagctcacg acgttgtaaa acgacggcca gtgaattgta 4620
atacgaactc ctatagggcg aattcaaaaa acccctcaag acccgtttag aggcccaag 4680
gggttatgct agtgaattct gcagggtacc cggggatcct ctagagatcc ctcgacctcg 4740
agatccattg tgctgg 4756

```

<210> 4

<211> 4643

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGX52

<400> 4

```

gagtgcacca tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcatca 60
ggcgaaattg taaacgttaa tattttgta aaattcgcgt taaatatttg ttaaaccagc 120
tcatttttta accaataggc cgaaatcggc aaaatccctt ataaatcaaa agaatagacc 180
gagatagggg tgagtgttgt tccagtttgg aacaagagtc cactattaaa gaacgtggac 240
tccaacgtca aagggcgaaa aaccgtctat cagggcgatg gccactacg tgaaccatca 300
cccaaatcaa gttttttgcg gtcgaggtgc cgtaaagctc taaatcggaa ccctaaaggg 360
agccccgat ttagagcttg acggggaaag cgggcgaacg tggcgagaaa ggaagggaag 420
aaagcgaaag gagcgggccc tagggcgctg gcaagtgtag cggtcacgct gcgcgtaacc 480
accacaccgg ccgcgcttaa tgcgcgcgta cagggcgcgt ccattcgcca ttcaggctgc 540
gcaactgttg ggaaggcgga tcgggtgcgg cctcttcgct attacgccag ctggcgaaag 600
ggggatgtgc tgcaaggcga ttaagttggg taacgccagg gttttccag tcacgacgtt 660
gtaaaacgac ggccagtga tttgaatacg actcactata gggcgaattc aaaaaacccc 720
tcaagaccgg tttagaggcc ccaaggggtt atgctagtga attctgcagg gtaccggggg 780
atcctctaga gatccctcga cctcgagatc cattgtgctg gcagccgatc tccgtcttgt 840
gaagatctac tccaccacca tccgtatcga tcagtcacac ctcaccggag aatctgtgtc 900
tgttatcaag cacaccgact ctgtgccaga tccacgcgct gttaccagg acaagaagaa 960
ttgtctgttc tcgggaacca atgtcgcac tggaaaggct cgtggaatcg tcttcggaac 1020
cggattgacc actgaaatcg gaaagatccg taccgaaatg gctgagaccg agaatgagaa 1080
gacaccactt caacagaagt tggacgaatt cggagagcaa ctttccaagg ttatctctgt 1140
tatttgcgtt gctgtttggg ctatcaacat tggacatttc aacgatccag ctacgggtgg 1200
atcatgggtt aaggagcaa tctactactt caaaatcgcc gttgctcttg ccgtcgctgc 1260
tattccagaa ggacttccag ctgtcatcac cacgtgcctt gccctcgga ctcgcccgtat 1320
ggccaagaag aacgctattg taagatccct tccatccgtc gaaactcttg gatgcacatc 1380
tgttatctgc tctgacaaga ctggaactct caccaccaac cagatgtctg tgtcaaagat 1440

```

gttcacgcgt	ggacaagcct	ctggagacaa	catcaacttc	accgagttcg	ccatctccgg	1500
atccacctac	gagccagtcg	gaaaggtttc	caccaatgga	cgtgaaatca	acccagctgc	1560
tggagaattc	gaatcactca	ccgagttggc	catgatctgc	gctatgtgca	atgattcatc	1620
tgttgattac	aatgagacca	agaagatcta	cgagaaagtc	ggagaagcca	ctgaaactgc	1680
tcttatcggt	cttgctgaga	agatgaatgt	tttcggaacc	tcgaaagccg	gactttcacc	1740
aaaggagctc	ggaggagttt	gcaaccgtgt	catccaacaa	aaatggaaga	aggagttcac	1800
actcgagttc	tcccgtgatc	gtaaattccat	gtccgcctac	tgcttcccag	cttccggagg	1860
atctggagcc	aagatgttcg	tgaagggagc	cccagaagga	gttctcggaa	gatgcaccca	1920
cgtcagagtt	aacggacaaa	aggttccact	cacctctgcc	atgactcaga	agattgttga	1980
ccaatgctgt	caatacggaa	ccggaagaga	tacccttcgt	tgtcttgccc	tcggccagca	2040
caatggatct	cgagggatct	tccataccta	caggttctgc	gcctgcaggt	cgcgcccgcg	2100
actctctaga	cgcgtaagct	tactagcata	accccttggg	gcctctaaac	gggtcttgag	2160
gggttttttg	agcttctcgc	cctatagtga	gtcgtattac	agcttgagta	ttctatagt	2220
tcacctaaat	agcttgcggt	aatcatggtc	atagctgttt	cctgtgtgaa	attgttatcc	2280
gctcacaatt	ccacacaaca	tacgagccgg	aagcataaag	tgtaaagcct	ggggtgccta	2340
atgagtgagc	taactcacat	taattgcgtt	gcgctcactg	cccgccttcc	agtcgggaaa	2400
cctgtcgtgc	cagctgcatt	aatgaatcgg	ccaacgcgcg	gggagaggcg	gtttgcgtat	2460
tgggcgctct	tccgcttcct	cgctcactga	ctcgctgcgc	tcggtcgttc	ggctgcggcg	2520
agcggtatca	gctcactcaa	aggcggtaat	acggttatcc	acagaatcag	gggataacgc	2580
aggaaagaac	atgtgagcaa	aaggccagca	aaaggccagg	aaccgtaaaa	aggccgcgtt	2640
gctggcgctt	tctgataggc	tccgcccccc	tgacgagcat	cacaaaaatc	gacgctcaag	2700
tcagaggttg	cgaaccgcga	caggactata	aagataccag	gcgtttcccc	ctggaagctc	2760
cctcgtgcgc	tctcctgttc	cgacctgcgc	gcttaccgga	tacctgtccg	cctttctccc	2820
ttcgggaagc	gtggcgcttt	ctcatagctc	acgctgtagg	tatctcagtt	cgggtgtagg	2880
cgttcgcctc	aagctgggct	gtgtgcacga	acccccggt	cagcccgacc	gctgcgcctt	2940
atccggtaac	tatcgtcttg	agtccaaccc	ggtaagacac	gacttatcgc	cactggcagc	3000
agccactggt	aacaggatta	gcagagcgag	gtatgtaggc	ggtgctacag	agttcttgaa	3060
gtggtggcct	aactacggct	acactagaag	gacagtattt	ggtatctgcg	ctctctgtaa	3120
gccagttacc	ttcggaaaaa	gagttggtag	ctcttgatcc	ggcaaaacaa	ccaccgctgg	3180
tagcgggtgt	ttttttgttt	gcaagcagca	gattacgcgc	agaaaaaaag	gatctcaaga	3240
agatcctttg	atcttttcta	cggggtctga	cgctcagttg	aacgaaaaact	cacgttaagg	3300
gatttttggtc	atgagattat	caaaaaggat	cttcacctag	atccttttaa	attaaaaatg	3360
aagtttttaa	tcaatctaaa	gtatatatga	gtaaacttgg	tctgacagtt	accaatgctt	3420
aatcagtgag	gcacctatct	cagcgatctg	tctatttctg	tcatccatag	ttgcctgact	3480
ccccgtcgtg	tagataacta	cgatacggga	gggcttacca	tctggcccca	gtgctgcaat	3540
gataccgcga	gaccacagct	caccggctcc	agatttatca	gcaataaacc	agccagccgg	3600
aaggggccgag	cgcagaagtg	gtcctgcaac	tttatccgcc	tccatccagt	ctattaattg	3660
ttgccgggaa	gctagagtaa	gtagttcgcc	agttaatagt	ttgcgcaacg	ttgttggcat	3720
tgtacagggc	atcgtggtgt	cacgctcgtc	gtttggtagt	gcttcattca	gctccgggtc	3780
ccaacgatca	aggcgagtta	catgatcccc	catgttgtgc	aaaaaagcgg	ttagctcctt	3840
cggtcctccg	atcgttgtca	gaagtaagtt	ggccgcagtg	ttatcactca	tggttatggc	3900
agcactgcat	aattctctta	ctgtcatgcc	atccgtaaga	tgcttttctg	tgactgggtg	3960
gtactcaacc	aagtcattct	gagaataccg	cgcccggcga	ccgagttgct	cttgcccggc	4020
gtcaatacgg	gataatagtg	tatgacatag	cagaacttta	aaagtgtcta	tcattggaaa	4080
acgttcttcg	gggcgaaaaa	tctcaaggat	cttaccgctg	ttgagatcca	gttcgatgta	4140
acccactcgt	gcacccaact	gatcttcagc	atcttttact	ttcaccagcg	tttctgggtg	4200
agcaaaaaa	ggaaggcaaa	atgccgcaaa	aaagggaata	agggcgacac	ggaaatgttg	4260
aatactcata	ctcttctttt	ttcaatatta	ttgaagcatt	tatcagggtt	attgtctcat	4320
gagcgggatac	atatttgaat	gtatttagaa	aaataaacia	ataggggttc	cgcgcacatt	4380
tccccgaaaa	gtgccacctg	acgtctaaga	aaccattatt	atcatgacat	taacctataa	4440
aaataggcgt	atcacgaggc	cctttcgtct	cgcgcgtttc	ggtgatgacg	gtgaaaacct	4500
ctgacacatg	cagctcccg	agacggtcac	agcttgtctg	taagcggatg	ccgggagcag	4560
acaagcccg	cagggcgcg	cagcgggtgt	tggcgggtgt	cggggctggc	ttactatgc	4620
ggcatcagag	cagattgtac	tga				4643

<210> 5

<211> 4454

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGX104

<400> 5

```

gagtgaccca tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcatca 60
ggcgaaattg taaacgttaa tattttgtta aaattcgcgt taaatatttg ttaaatacagc 120
tcatttttta accaataggc cgaaatccgc aaaatccctt ataaatcaaa agaatagacc 180
gagatagggg tgagtgttgt tccagtttgg aacaagagtc cactattaaa gaacgtggac 240
tccaaacgtca aagggcgaaa aaccgtctat cagggcgatg gccactacg tgaaccatca 300
cccaaatcaa gttttttgcg gtcgaggtgc cgtaaagctc taaatcgga ccctaaaggg 360
agcccccgat ttagagcttg acggggaaag cggcgaaacg tggcgagaaa ggaagggag 420
aaagcgaaag gagcgggcgc tagggcgctg gcaagtgtag cggtcacgct gcgcgtaacc 480
accacaccgc ccgcgcttaa tgcgccgcta cagggcgcgt ccattcgcca ttcaggctgc 540
gcaactgttg ggaagggcga tcggtgcggg cctcttcgct attacgccag ctggcgaaag 600
ggggatgtgc tgcaaggcga ttaagttggg taacgccagg gttttccag tcacgacgtt 660
gtaaaacgac ggccagtga ttaagttggg taacgccagg gttttccag tcacgacgtt 660
tcaagaccgc ttttagagcc ccaaggggtt atgctagtga attctgcagg gtacccgggg 780
atcctctaga gatccctcga cctcgagatc cattgtgctg gaccgtggta ctcttatgga 840
gctcggaatc tcgccaatcg tcacttcttg acttatcatg caacttctcg ccggagccaa 900
gatcatcgaa gtcggagaca cacaaagga ccgtgctctt ttcaacggag ccagaaatg 960
taagccgaaa agtgtgtgtt ttcaatctct aatttttgaa cttttcagtg ttcggtatgg 1020
tcatcactgt tggacaagct attgtctacg tcatgtccgg actctacgga gagccatcgg 1080
aaatcggagc tggaatctgt ctcttatcgc tcgtccaaact cgttattgcc ggtctcatcg 1140
tcctccttct cgacgagctt ctccaaaagg gatattggtc cggatccgga atttctctct 1200
tcattgccac caacatctgt gaaaccattg tctggaaggc attctccccg gcaacaatga 1260
acaccggacg tggaaaccgag ttccaaggag ccgtcattgc tcttttccat ctcttgcca 1320
cccgtccga caaggtccgt gcccttcgtg aggccttcta ccgtcaaaac cttccaaact 1380
tgatgaactt gatggctact ttccctcggt ttgcggtggg tatctacttc caaggattcc 1440
gtgtcgacct cccaatcaag tctgcccgt accgtggaca atacagcagc taccatca 1500
agctcttcta cacctccaac attccaatca tcttcaatc tgctctcgtc tccaacctct 1560
acgttatctc tcaggtttgt tgcattctcag tagtaccgtt agatgtttat ctttctctag 1620
aggggtcaagt tggccgagaa attttttgag ttcatctca agtctgatgg aaaatgttta 1680
tttttcagat gctcgccgga aagttcggag gaaacttctt catcaacctt ctcggtacct 1740
ggtcggataa caccggatac agaagctacc caactggagg actctgctac tatctttcac 1800
caccagagtc tcttgacac atcttcgaag acccaatcca ctgcaccagc acaatggatc 1860
tcgagggatc ttccatacct accagttctg ccctcgcagg tcgcgccgc gactctctag 1920
acgcgtaagc ttactagcat aacccttgg ggctctaaa cgggtcttga ggggtttttt 1980
gagcttctcg cctatagtg agtcgtatta cagcttgagt attctatagt gtcacctaaa 2040
tagcttggcg taatcatggt catagctgtt tctgtgtga aattgttatc cgctcacaat 2100
tccacacaa atacgagccg gaagcataaa gtgtaaagcc tggggtgcct aatgagttag 2160
ctaactcaca ttaattgcgt tgcgctcact gccgcgtt cagtcgggaa acctgtcgtg 2220
ccagctgcat taatgaatcg gccaacgcgc ggggagaggc ggtttgcgta ttgggcgctc 2280
ttccgcttcc tcgctcactg actcgctgcg ctcggtcggt cggctgcggc gagcggtatc 2340
agctcactca aaggcggtaa tacggttatc cacagaatca ggggataacg caggaaagaa 2400
catgtgagca aaaggccagc aaaaggccag gaaccgtaaa aaggccgcgt tgctggcgtt 2460
tttcgatagg ctccgcccc ctgacgagca tcacaaaaat cgacgctcaa gtcagaggtg 2520
gcgaaacccg acaggactat aaagatacca ggcgtttccc cctggaagct ccctcgtgcg 2580
ctctcctgtt ccgaccctgc cgcttaccgg atacctgtcc gcctttctcc cttcggaag 2640
cgtggcgctt tctcatagct cacgctgtag gtatctcagt tcggtgtagg tcgttcgctc 2700
caagctgggc tgtgtgcacg aacccccgt tcagccgcac cgctgcgcct tatccggtaa 2760
ctatcgtctt gagtccaacc cggtaagaca cgacttatcg ccactggcag cagccactgg 2820
taacaggatt agcagagcga ggtatgtagg cgggtgtaca gagttcttga agtgggtggc 2880
taactacggc tacactagaa ggacagtatt tggatctgc gctctgctga agccagttac 2940
cttcggaaaa agagttggtg gctcttgatc cggcaaaaa accaccgtg gtagcgggtg 3000
ttttttgtt tgcaagcagc agattacgcg cagaaaaaa ggatctcaag aagatccttt 3060
gatcttttct acgggggtctg acgctcagtg gaacgaaaac tcacgttaag ggattttggt 3120

```



```

catgagatta tcaaaaagga tcttcaccta gatcctttta aattaaaaat gaagttttta 3180
atcaatctaa agtatatatg agtaaaacttg gtctgacagt taccaatgct taatcagtga 3240
ggcacctatc tcagcgatct gtctatttcg ttcattccata gttgcctgac tccccgtcgt 3300
gtagataact acgatacggg agggccttacc atctggcccc agtgctgcaa tgataccgcg 3360
agaccacgc tcaccggctc cagattttatc agcaataaac cagccagccg gaagggccga 3420
gcgcagaagt ggtcctgcaa ctttatccgc ctccatccag tctattaatt gttgccggga 3480
agctagagta agtagttcgc cagttaatag tttgcgcaac gttggttgga ttgctacagg 3540
catcgtggtg tcacgctcgt cgtttggtat ggcttcattc agctccggtt cccaacgac 3600
aaggcgagtt acatgatccc ccatgttggtg caaaaaagcg gttagctcct tcggctcctc 3660
gatcgttgtc agaagtaagt tggccgcagt gttatcactc atgggtatgg cagcactgca 3720
taattctctt actgtcatgc catcogtaag atgcttttct gtgactggtg agtactcaac 3780
caagtcattc tgagaatacc gcgcccggcg accgagttgc tcttgccggg cgtcaatacg 3840
ggataatagt gtatgacata gcagaacttt aaaagtgtc atcattggaa aacgttcttc 3900
ggggcgaaaa ctctcaagga tcttaccgct gttgagatcc agttcgatgt aaccactcg 3960
tgcacccaac tgatcttcag catcttttac tttcaccagc gtttctgggt gagcaaaaac 4020
aggaaggcaa aatgccgcaa aaaagggaat aaggggcgaca cggaaatgtt gaatactcat 4080
actcttcctt tttcaatatt attgaagcat ttatcagggt tattgtctca tgagcggata 4140
catatttgaa tgtatttaga aaaataaaca aataggggtt ccgcgcacat ttccccgaaa 4200
agtgccacct gacgtctaag aaaccattat tatcatgaca ttaacctata aaaataggcg 4260
tatcacgagg ccctttcgtc tcgcgcggtt cgggtgatgc ggtgaaaacc tctgacacat 4320
gcagctcccg gagacggtca cagcttgctt gtaagcggat gccgggagca gacaagcccg 4380
tcagggcgcg tcagcgggtg ttggcgggtg tcggggctgg cttactatg cggcatcaga 4440
gcagattgta ctga 4454

```

<210> 6

<211> 4701

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGZ18

<400> 6

```

accagcttt cttgtacaaa gtggtgatct ttccagcaca atggatctcg agggatcttc 60
catacctacc agttctgcgc ctgcaggctg cgccgcgac tctctagacg cgtaagctta 120
ctagcataac cccttggggc ctctaaacgg gtcttgaggg gttttttgag cttctcgcgc 180
tatagtgagt cgtattacag cttgagtatt ctatagtgtc acctaaatag cttggcgtaa 240
tcattggtcat ccctgtttcc tgtgtgaaat tggtatccgc tcacaattcc acacaacata 300
cgagccggaa gcataaagtg taaagcctgg ggtgcctaata gagtgagcta actcacatta 360
attgcgttgc gctcactgcc cgctttccag tcgggaaaacc tgcgtgcca gctgcattaa 420
tgaatcgccc aacgcgcggg gagaggcggg ttgcgtattg ggcgctcttc cgcttcctcg 480
ctcactgact cgctgcgctc ggtcgttcgg ctgcggcgag cggtatcagc tcaactcaaa 540
gcggtataac ggttatccac agaatacagg gataacgcag gaaagaacat gtgagcaaaa 600
ggccagcaaa aggccaggaa ccgtaaaaag gccgcgttgc tggcggtttt cgataggctc 660
cgccccctg acgagcatca caaaaatcga cgctcaagtc agaggtggcg aaaccgcaca 720
ggactataaa gataccaggc gtttccccct ggaagctccc tcgtgcgctc tctgttccg 780
accctgccgc ttaccggata cctgtccgcc tttctccctt cgggaagcgt ggcgctttct 840
catagctcac gctgtaggta tctcagttcg gtgtaggctg ttgcgtccaa gctgggctgt 900
gtgcacgaac cccccgttca gcccgaccgc tgcgccttat ccggtacta tcgtcttgag 960
tccaaccggg taagacacga cttatcgcca ctggcagcag ccactggtaa caggattagc 1020
agagcgagggt atgtaggcgg tgctacagag ttcttgaaat ggtggcctaa ctacggctac 1080
actagaagga cagtatttgg tatctgcgct ctgctgaagc cagttacctt cggaaaaaga 1140
gttggttagct cttgatccgg caaacaacc accgctggta gcgggtggtt ttttgtttgc 1200
aagcagcaga ttacgcgcag aaaaaaagga tctcaagaag atcctttgat cttttctacg 1260
gggtctgacg ctacgtggaa cgaaaactca cgtaagggg ttttggatc gagattatca 1320
aaaaggatct tcacctagat ctttttaaat caaatctaa gtttttaaat aatctaaagt 1380
atatatgagt aaacttggtc tgacagttac taatgcttaa tcagtggagc acctatctca 1440
gcgatctgtc tatttcgttc atccatagtt gcctgactcc ccgtcgtgta gataactacg 1500

```

```

atacggggagg gcttaccatc tggccccagt gctgcaatga taccgcgaga cccacgctca 1560
ccggctccag atttatcagc aataaaccag ccagccggaa gggccgagcg cagaagtggg 1620
cctgcaactt tatccgcctc catccagtct attaatgtt gccgggaagc tagagtaagt 1680
agttcgccag ttaatagttt gcgcaacggt gttggcattg ctacaggcat cgtgggtgtca 1740
cgctcgctgt ttggtatggc ttcattcagc tccggttccc aacgatcaag gcgagttaca 1800
tgatccccc tgtgtgcaa aaaagcgggt agctccttcg gtcctccgat cgttgtcaga 1860
agtaagtgtg ccgcagtgtt atcactcatg gttatggcag cactgcataa ttctcttact 1920
gtcatgccat ccgtaagatg cttttctgtg actggtgagt actcaaccaa gtcattctga 1980
gaataccgcg cccggcgacc gagttgctct tgcccgcggt caatacggga taatagtgtg 2040
tgacatagca gaactttaaa agtgctcatc attgaaaaac gttcttcggg gcgaaaactc 2100
tcaaggatct taccgctgtt gagatccagt tcgatgtaac ccactcgtgc acccaactga 2160
tcttcagcat cttttacttt caccagcgtt tctgggtgag caaaaacagg aaggcaaaat 2220
gccgcaaaaa agggaataag ggcgacacgg aaatgttgaa tactcatact cttccttttt 2280
caatattatt gaagcattta tcagggttat tgtctcatga gcggatacat atttgaatgt 2340
atthagaaaa ataaacaaat aggggttccg cgcacatttc cccgaaaagt gccacctgac 2400
gtctaagaaa ccattattat catgacatta acctataaaa ataggcgtat cacgaggccc 2460
tttcgtctcg cgcgtttcgg tgatgacggt gaaaacctct gacacatgca gctcccggag 2520
acggtcacag cttgtctgta agcggatgcc gggagcagac aagcccgta gggcgcgta 2580
gcgggtgttg gcgggtgtcg gggctggctt aactatcgcg catcagagca gattgtactg 2640
agagtgcacc atatgcggtg tgaaataccg cacagatgcg taaggagaaa ataccgcata 2700
aggcgaaatt gtaaacgtta atattttgtt aaaattcgcg ttaaatattt gttaaatcag 2760
ctcatttttt aaccaatagg ccgaaatcgg caaaatccct tataaatcaa aagaatagac 2820
cgagataggg ttgagtgttg ttccagtttg gaacaagagt ccactattaa agaacgtgga 2880
ctccaacgct aaagggcgaa aaaccgtcta tcagggcgat ggcccactac gtgaaccata 2940
acccaaatca agttttttgc ggtcgaggtg ccgtaaagct ctaaatacgg accctaagg 3000
gagccccga tttagagctt gacggggaaa gccggcgaaac gtggcgagaa aggaaggga 3060
gaaagcgaaa ggagcgggcg ctagggcgct ggcaagtgtg gcggtcacgc tgcgcgtaac 3120
caccacaccc gccgcgctta atgcgcgct acagggcgcg tccattcgcc attcaggctg 3180
cgcaactgtt ggggaaggcg atcgggtcgg gcctcttcgc tattacgcca gctggcgaaa 3240
gggggatgtg ctgcaaggcg attaagttgg gtaacgccag ggttttccca gtcacgacgt 3300
tgtaaaacga cggccagtga attgtaatac gactcactat agggcgaaat caaaaaaccc 3360
ctcaagaccc gtttagaggg cccaaggggt tatgctagtg aattctgcag ggtaccggg 3420
gatcctctag agatccctcg acctcgagat ccattgtgct ggaaagcctt tgcagggctg 3480
gcaagccacg tttggtggtg gcgaccatcc tccaaaatca acaagtttgt acaaaaaagc 3540
aggctatgcc aagtacatgt cgattgcgta cgcgttcgta atgttggtg tgtagtcgc 3600
taccagcagt caaattgttc tcgagagtgc gtttttacat tatcccttca tctgattac 3660
gacaattttc agctgttctc gtcctacat ctctcttcat tgtcacaatg gtcggaatct 3720
tcttctttgc tgcattgtct catccaaaag aattcacgaa tattatccat ggtgtcgtat 3780
tcttctcat gattccatct acatatgtgt tcctcacttt atattcgctc atcaatctca 3840
acgttatcac gtggggaact cgtgaagctg tcgctaaggc aacgggacaa aagacgaaaa 3900
aagcgctat ggaacaattt atagacagag tgattgatat tgtgaaaaag ggattcagat 3960
taatcagttg tcgggagaag aaggaacatg aagagagacg agagaaaatg gaaaaagaaa 4020
tgagagaaat ggagctagcc ttgagaagta ttgaggttat ctttaacttt agaaatgtga 4080
aattaataat ttattttcag agtggtgccg acgtgaagaa aattctcgat gcaacagagg 4140
agaaggagaa acgtgaagaa gaaactcaaa ctgcagattt tccgattgaa gagaacgtag 4200
agaagactca aaaagagatt .cagaaggcaa accgttatgt gtggatgaca agtcatagct 4260
tgaaagtgtg tgaacgagga aaactgaaaa gtgcggaaaa ggttttctgg aacgagctca 4320
tcaatgcata tctgaaaccg atcaagacga cgccagctga aatgaaagcc gtcgccgaag 4380
gattggcttc tctacgaaat cagattgctt tcactattct tctcgtaaat tctcttcttg 4440
ctcttgccat ctttttgatt cagaaacaca aaaatgtgct cagcatcaag ttctcgccaa 4500
tcagtaagca atattacctt tatggtcaat tcaaaaaatt tgtttttttt ttctagaaaa 4560
cttccgatgg acgaaaatga atgagatgac tggacaatac gaggaaaccg atgaaccatt 4620
aaaaatagat ccacttgga tgggaattgt tgttttcctt ctaattatct tttttgttca 4680
aactctcgga atgcttctcc a 4701

```

<210> 7

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide primer C04H5.6F

<400> 7

tgctcagaga gtttctcaac gaacc

25

<210> 8

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide
primer C04H5.6R

<400> 8

caatgttagt tgctaggacc acctg

25

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide
primer K11D9.2bF

<400> 9

cagccgatct ccgtcttgtg

20

<210> 10

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide
primer K11D9.2bR

<400> 10

ccgagggcaa gacaacgaag

20

<210> 11

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide
primer Y57G11C.15F

<400> 11

accgtggtac tcttatggag ctcg

24

<210> 12

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Oligonucleotide
primer Y57G11C.15R

<400> 12
tgcagtggat tgggtcttcg

20

<210> 13
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Oligonucleotide
primer T25G3.2F

<400> 13
ggggacaagt ttgtacaaaa aagcaggcta tgccaagtac atgtcgattg cg

52

<210> 14
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Oligonucleotide
primer T25G3.2R

<400> 14
ggggaccact ttgtacaaga aagctgggtt ggagaagcat tccgagagtt tg

52

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 July 2001 (05.07.2001)

PCT

(10) International Publication Number
WO 01/48183 A3

- (51) International Patent Classification⁷: C12N 15/10, 9/22, C07K 14/435, C12N 15/66, 15/70, 1/00
- (74) Agent: BAYLISS, Geoffrey, Cyril; Boulton Wade Tennant, Verulam Gardens, 70 Gray's Inn Road, London WC1X 8BT (GB).
- (21) International Application Number: PCT/EP00/13149
- (22) International Filing Date:
22 December 2000 (22.12.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
9930691.2 24 December 1999 (24.12.1999) GB
- (71) Applicant (*for all designated States except US*): DEV-GEN NV [BE/BE]; Technologiepark 9, B-9052 Zwijnaarde (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): PLAETINCK, Geert [BE/BE]; Pontstraat 16, B-9820 Merelbeke (BE). MORTIER, Katherine [BE/BE]; Paddenhoek 20, B-9830 St.-Martens Latem (BE). LISSENS, Ann [BE/BE]; Tiensesteenweg 137, B-3010 Kessel-Lo (BE). BOGAERT, Thierry [BE/BE]; Wolvendreef 26g, B-8500 Kortrijk (BE).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (88) Date of publication of the international search report:
6 December 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 01/48183 A3

(54) Title: IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA INHIBITION

(57) Abstract: There are described ways of improving the efficiency of double stranded RNA inhibition as a method of inhibiting gene expression in nematode worms such as *C. elegans*. In particular, the invention relates to the finding that changes in the genetic background of *C. elegans* result in increased sensitivity to double-stranded RNA inhibition.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/13149

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/10 C12N9/22 C07K14/435 C12N15/66 C12N15/70
C12N1/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TIMMONS L ET AL: "Specific interference by ingested dsRNA" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 395, no. 6705, 29 October 1998 (1998-10-29), page 854 XP002103601 ISSN: 0028-0836 the whole document ---	1-4, 12-21, 23-25, 28-31, 34-39
A	FIRE A ET AL: "Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans" NATURE, GB, MACMILLAN JOURNALS LTD. LONDON, vol. 391, 19 February 1998 (1998-02-19), pages 806-811, XP002095876 ISSN: 0028-0836 cited in the application the whole document ---	1-4

-/--



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

5 July 2001

Date of mailing of the international search report

20/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mateo Rosell, A.M.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/13149

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SHARP PHILLIP A: "RNAi and double-strand RNA." GENES & DEVELOPMENT, vol. 13, no. 2, 15 January 1999 (1999-01-15), pages 139-141, XP002171268 ISSN: 0890-9369 the whole document ---	1-4
A	RAY C ET AL: "GUT-SPECIFIC AND DEVELOPMENTAL EXPRESSION OF A CAENORHABDITIS ELEGANS CYSTEINE PROTEASE GENE" MOLECULAR AND BIOCHEMICAL PARASITOLOGY,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 51, 1992, pages 239-249, XP000572340 ISSN: 0166-6851 abstract ---	2-4,8
A	RAND J B ET AL: "GENETIC PHARMACOLOGY: INTERACTIONS BETWEEN DRUGS AND GENE PRODUCTS IN CAENORHABDITIS ELEGANS" METHODS IN CELL BIOLOGY,LONDON,GB, vol. 84, 1995, pages 187-204, XP000956211 page 190, paragraph 1 -page 194, paragraph 4 ---	1-4,8
A	AVERY LEON ET AL: "The Caenorhabditis elegans unc-31 gene affects multiple nervous system-controlled functions." GENETICS, vol. 134, no. 2, 1993, pages 455-464, XP001011453 ISSN: 0016-6731 the whole document ---	2-4,8
A	TAGESSON C ET AL: "INFLUENCE OF SURFACE-ACTIVE FOOD ADDITIVES ON THE INTEGRITY AND PERMEABILITY OF RAT INTESTINAL MUCOSA" FOOD AND CHEMICAL TOXICOLOGY, vol. 22, no. 11, 1984, pages 861-864, XP001009621 ISSN: 0278-6915 the whole document --- -/--	8

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/13149

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	<p>LYON CHRISTOPHER J ET AL: "The C. elegans apoptotic nuclease NUC-1 is related in sequence and activity to mammalian DNase II."</p> <p>GENE (AMSTERDAM), vol. 252, no. 1-2, 11 July 2000 (2000-07-11), pages 147-154, XP001009494 ISSN: 0378-1119 abstract; figure 3 page 151, right-hand column, paragraph 2 -page 153, right-hand column, paragraph 2</p> <p>---</p>	6,7
P,X	<p>WO 00 01846 A (MORTIER KATHERINE ;DEVGEN NV (BE); BOGAERT THIERRY (BE); PLAETINCK) 13 January 2000 (2000-01-13) cited in the application</p> <p>page 8, line 9 -page 10, line 22 page 12, line 14 -page 23, line 2 figures 5,9; examples 1-4</p> <p>---</p>	1-4, 12-21, 23-25, 28-31, 34-39
P,X	<p>WO 00 63425 A (FEICHTINGER RICHARD ;BEGHYN MYRIAM (BE); DEVGEN NV (BE); BOGAERT T) 26 October 2000 (2000-10-26) abstract page 2, line 14-30 page 6, line 18-33 page 7, line 12 -page 9, line 28 page 12, line 20 -page 13, line 25; example 3</p> <p>---</p>	2-5,8,9, 29-33
T	<p>TIMMONS LISA ET AL: "Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in Caenorhabditis elegans."</p> <p>GENE (AMSTERDAM), vol. 263, no. 1-2, 2001, pages 103-112, XP001009512 ISSN: 0378-1119 the whole document</p> <p>-----</p>	1-4, 12-21, 23-26, 28-31, 34-39

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/13149

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0001846 A	13-01-2000	AU 4907999 A EP 1093526 A GB 2349885 A NO 20010019 A	24-01-2000 25-04-2001 15-11-2000 05-03-2001
WO 0063425 A	26-10-2000	AU 3984600 A GB 2351152 A	02-11-2000 20-12-2000